imatinib mesylate has been researched along with Recrudescence in 289 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 148 (51.21) | 29.6817 |
| 2010's | 122 (42.21) | 24.3611 |
| 2020's | 19 (6.57) | 2.80 |
| Authors | Studies |
|---|---|
| Atenafu, EG; Bence-Bruckler, I; Busque, L; Delage, R; Forrest, D; Kamel-Reid, S; Keating, MM; Kim, DDH; Kim, TS; Laneuville, P; Leber, B; Liew, E; Lipton, JH; Novitzky Basso, I; Paulson, K; Savoie, L; Stockley, T; Xenocostas, A | 1 |
| Atsuta, Y; Cho, R; Dobashi, N; Doki, N; Fujisawa, S; Fujita, H; Hagihara, M; Hata, T; Hatta, Y; Hayakawa, F; Hiramoto, N; Hirano, D; Ishikawa, Y; Ito, T; Kako, S; Kamae, T; Kobayashi, Y; Matsuda, M; Miyazaki, Y; Naoe, T; Nishiwaki, S; Ohtake, S; Onoda, M; Ozawa, Y; Sakura, T; Suehiro, Y; Sugiura, I; Tanaka, M; Taniguchi, Y; Tsuji, M; Ueda, Y; Yokoyama, H | 1 |
| Deng, H; Di, Q; Li, BY; Qin, L; Zhao, Y | 1 |
| Alonso, N; Bermúdez, A; Cano-Ferri, I; Esteban, D; Esteve, J; García-Calduch, O; García-Fortes, M; García-Sanz, R; Genescà, E; González-Campos, J; Martínez, P; Martínez-Lopez, J; Mercadal, S; Montesinos, P; Ribera, J; Ribera, JM; Torrent, A | 1 |
| Jabbour, E; Kantarjian, H | 1 |
| Hwang, EJ; Kim, DW; Kim, DY; Kim, E; Kim, JY; Lee, J | 1 |
| Akın, MG; Çiftçiler, R; Erat, Z; Eşkazan, AE | 1 |
| Boye, K; Hovig, E; Khelik, K; Meza-Zepeda, LA; Myklebost, O; Nakken, S; Namløs, HM; Vodák, D | 1 |
| Argüello, RJ; Chen, MH; Chen, X; Chimge, NO; Du, J; Gonzalez, PG; Hurwitz, S; Jin, V; Kahn, M; Kim, YM; Nguyen, C; Ogana, H; Ono, M; Teo, JL; Wu, X; Zhao, Y | 1 |
| Albayrak, M; Aydın Kaynar, L; Başer Dikyar, AA; Can, F; Çeneli, Ö; Gökçen, S; Karakuş, S; Öcal, R; Özkurt, ZN; Pepeler, S; Savaş, EM; Yağcı, M; Yıldız, A; Yılmaz, S | 1 |
| Akashi, K; Imamura, Y; Ishikawa, J; Kadowaki, N; Kanakura, Y; Kawaguchi, T; Kuroda, J; Matsumura, I; Miyamoto, T; Nagafuji, K; Nakamae, H; Shimose, T; Yamazaki, H | 1 |
| Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z | 1 |
| Cayuela, JM; Delord, M; Loiseau, C; Rousselot, P; Spentchian, M | 1 |
| Arous, R; Benchabane, H; Boudiaf, H; Boukhelal, H; Chikhi, L; Ezziane, K; Hakem, S; Himrane, M; Rouis, NO | 1 |
| Deng, L; Fan, Z; Huang, F; Jin, H; Li, X; Liang, X; Lin, D; Lin, R; Liu, H; Liu, Q; Ma, L; Nie, D; Sun, J; Xu, D; Xu, N; Xuan, L; Ye, J; Zhang, Y | 1 |
| Breccia, M; Colafigli, G; Di Prima, A; Efficace, F; Foà, R; Martelli, M; Scalzulli, E | 1 |
| Abdo, ANR; Bendit, I; Maciel, FVR; Nardinelli, L; Pereira, TDM; Rocha, V; Santos, FM; Seguro, FS | 1 |
| Adiko, D; Bauduer, F; Bijou, F; Charles-Nelson, A; Dagada, C; Dulucq, S; Durrieu, F; Etienne, G; Faberes, C; Fort, MP; Katsahian, S; Klein, E; Lascaux, A; Lenoir, C; Lifermann, F; Madene, S; Mahon, FX; Moldovan, M; Robbesyn, F; Schmitt, A; Turcq, B; Versmée, L | 1 |
| Campos-Gazeau, F; Chalayer, E; De Broucker, T; Denier, C; Groh, M; Guidoux, C; Hamidou, M; Hunault, M; Kahn, JE; Lefèvre, G; Lyoubi, A; Meunier, R; Muron, T; Rohmer, J; Sène, D; Slama, B; Tennenbaum, J; Venditti, L | 1 |
| Beitzen-Heineke, A; Fiedler, W; Reinert, J; Schwartz, S; Stelljes, M; Wethmar, K | 1 |
| Jin, J; Li, C; Lou, Y; Ma, Y; Mai, W; Mao, L; Meng, H; Qian, W; Suo, S; Tong, H; Wei, J; Xu, W; Yu, W | 1 |
| Bakhshi, S; Gogia, A; Gupta, YK; Harivenkatesh, N; Kabra, M; Kumar, L; Sharma, A; Shastri, SS; Velpandian, T | 1 |
| Fang, Q; Huang, J; Liu, P; Ma, D; Ren, M; Wang, J; Wang, P; Yu, M; Yu, Z; Zhe, N | 1 |
| Charbonnier, A; Dubruille, V; Dulphy, N; Etienne, G; Gardembas, M; Guerci-Bresler, A; Guilhot, F; Guilhot, J; Henry, G; Huguet, F; Ianotto, JC; Khaznadar, Z; Legros, L; Mahon, FX; Maloisel, F; Moins-Teisserenc, H; Nicolini, F; Rea, D; Rousselot, P; Toubert, A; Villemagne, B | 1 |
| Hamid, M; Jalaeikhoo, H; Rostami, G | 1 |
| Chen, H; Chen, YH; Huang, XJ; Lai, YY; Liu, KY; Liu, YR; Qin, YZ; Wang, Y; Xu, LP; Zhang, XH | 1 |
| Akram, M; Quraishi, AM; Saeed, S; Tahir, M | 1 |
| Ghirdaladze, D; Kirtava, T; Vatsadze, T | 1 |
| Alten, J; Aricò, M; Biondi, A; Bleckmann, K; Castor, A; Cavé, H; Cazzaniga, G; Conter, V; De Lorenzo, P; Escherich, G; Ferrari, GM; Gandemer, V; Hancock, J; Köhler, R; Leoni, V; Madsen, HO; Pieters, R; Röttgers, S; Saha, V; Schrappe, M; Stadt, UZ; Stary, J; Valsecchi, MG; van der Velden, V; Zuna, J | 1 |
| Abid, MB; de Mel, S; Ng, SY; Poon, KS; Poon, LM; Wang, S | 1 |
| Chen, H; Huang, XJ; Jia, JS; Jiang, B; Jiang, H; Jiang, Q; Liu, KY; Qin, YZ; Ruan, GR; Wang, J; Xu, LP; Zhang, XH; Zhao, T | 1 |
| Hirano, M; Imai, Y; Imoto, S; Jimbo, K; Kawamata, T; Miyano, S; Ochi, K; Ogawa, M; Ohno, N; Shimizu, E; Takahashi, N; Tojo, A; Uchimaru, K; Yamaguchi, R; Yokoyama, K; Yokoyama, N | 1 |
| Gaynon, PS | 1 |
| Fujikawa, Y; Hasuo, K; Jin, Y; Kakazu, A; Koumori, K; Masuda, M; Mikayama, Y; Watanabe, T | 1 |
| Akabori, H; Iida, H; Kaida, S; Kitamura, N; Miyake, T; Mori, T; Shimizu, T; Sonoda, H; Takebayashi, K; Tani, M; Terada, Y; Ueki, T; Yamaguchi, T | 1 |
| Aoyama, T; Cho, H; Hayashi, T; Kano, K; Maezawa, Y; Masuda, M; Ogata, T; Oshima, T; Rino, Y; Sato, T; Yamada, T; Yoshikawa, T; Yukawa, N | 1 |
| Bizarro, S; Campilho, F; Campos, A; Cerveira, N; Correia, C; Ferreira, RB; Leite, L; Lisboa, S; Pinho Vaz, C; Santos, R; Teixeira, MR; Torres, L; Vieira, J | 1 |
| Chen, H; Chen, YH; Cheng, YF; Han, W; Huang, XJ; Jia, YP; Liu, KY; Lu, AD; Sun, YQ; Suo, P; Wang, Y; Wu, J; Xu, LP; Xue, YJ; Yan, CH; Zhang, LP; Zuo, YX | 1 |
| Leotta, S; Manzella, L; Massimino, M; Milone, G; Pennisi, MS; Puma, A; Romano, C; Sapienza, G; Scalise, L; Stagno, F; Stella, S; Tirrò, E; Vitale, SR | 1 |
| Angmo, D; Kamble, N; Roop, P; Tomar, AS | 1 |
| Apperley, JF; Byrne, J; Clark, RE; Copland, M; de Lavallade, H; Foroni, L; Milojkovic, D; O'Brien, SG; Osborne, W; Pocock, C; Polydoros, F; Read, L; Robinson, L; Rothwell, K | 1 |
| Xicoy, B; Zamora, L | 1 |
| Alimoghaddam, K; Ansari, S; Arjmandi Rafsanjani, K; Bahosh, G; Behfar, M; Darbandi, B; Ghavamzadeh, A; Hamidieh, AA; Soroush, A | 1 |
| Arthur, C; Branford, S; Dang, P; Filshie, RJ; Goyne, JM; Grigg, AP; Hughes, TP; Melo, JV; Mills, AK; Ross, DM; Schwarer, AP; Seymour, JF; Slader, C; White, DL; Yeung, DT | 1 |
| Abdulkadyrov, KM; Bessmel'tsev, SS; Martynkevich, IS; Romanenko, NA; Rugal', VI; Udal'eva, VIu; Zenina, MN | 1 |
| Dai, M; Fan, Z; Feng, R; Huang, F; Jin, H; Liu, Q; Sun, J; Wei, Y; Xiong, Y; Xu, D; Zhang, Y; Zhou, H | 1 |
| Hanada, N; Hori, K; Kawata, K; Okamura, S; Tomiyama, N | 1 |
| Agape, P; Cayuela, JM; Charbonnier, A; Chomel, JC; Cony-Makhoul, P; Escoffre-Barbe, M; Etienne, G; Gardembas, M; Guerci-Bresler, A; Guilhot, F; Guilhot, J; Mahon, FX; Nicolini, FE; Prost, S; Réa, D; Reiffers, J; Rousselot, P; Roy, L; Spentchian, M; Tulliez, M; Turhan, A; Varet, B | 1 |
| Akahoshi, S; Inoue, K; Kiyota, Y; Kiyozumi, Y; Motooka, Y; Yamaguchi, R; Yoshida, Y | 1 |
| Hjorth-Hansen, H; Koskenvesa, P; Kreutzman, A; Lundán, T; Mustjoki, S; Pihlman, M; Porkka, K; Räsänen, A; Remes, K; Rohon, P; Simonsson, B; Vakkila, E; Vakkila, J; Vapaatalo, M | 1 |
| Ikehara, T; Inoue, T; Kanazawa, A; Nishiguchi, Y; Shimizu, S; Toyokawa, T; Tsukamoto, T; Yamamoto, A; Yamashita, Y | 1 |
| Ebisui, C; Kinuta, M; Murakami, M; Murata, K; Nakagomi, N; Okada, K; Okamura, S; Tamai, M | 1 |
| Aledo, A; Borowitz, MJ; Bowman, WP; Camitta, B; Carroll, A; Carroll, WL; Davies, SM; Devidas, M; Gaynon, PS; Heerema, NA; Hunger, SP; Jorstad, D; Rutledge, R; Sather, H; Schultz, KR; Slayton, WB; Trigg, M; Winick, N; Zheng, HW | 1 |
| Bassan, R; Imbergamo, S; Maino, E; Sancetta, R; Scattolin, AM; Vespignani, M; Viero, P | 1 |
| McElligott, F; O'Marcaigh, A; O'Rafferty, C; Smith, O; Storey, L | 1 |
| Iwasaki, K; Kagaya, A; Kurata, Y; Matsubara, H; Nimura, Y; Sakuma, Y; Takaishi, S; Tohma, T; Yamamoto, Y | 1 |
| Bai, Y; Chang, Z; Guo, H; Liao, H; Liu, T; Liu, Y; Qiu, S; Wang, X; Yan, X | 1 |
| Liang, H | 1 |
| Abdelaal, M; Abrar, MB; Absi, A; Al-Amri, A; Alsaeed, A; Alshehri, MA; Alsobhi, E; Alzahrani, Z; Bayashoot, S; El-Hemaidi, I; Hashem, H; Merdad, A; Radi, S; Shiekhi, H; Warsi, A | 1 |
| Armand, P; Brown, JR; Cote, G; Dal Cin, P; Dorfman, DM; Fisher, DC; Freedman, AS; Hochberg, E; Jacobsen, E; LaCasce, A; Neuberg, D; Pozdnyakova, O; Redd, R; Shahsafaei, A | 1 |
| Horibe, K; Kato, I; Kato, K; Kato, M; Kawasaki, H; Kodama, Y; Kudo, K; Manabe, A; Matsumoto, K; Saito, AM; Saito, T; Sato, A; Shimada, H; Tsurusawa, M; Yabe, H | 1 |
| Chen, H; Chen, YH; Han, W; Huang, XJ; Liu, KY; Liu, YR; Qin, YZ; Wang, Y; Xu, LP; Zhang, XH | 1 |
| Pagani, IS; Pirrone, C; Porta, G | 1 |
| Egawa, C; Goto, T; Hashimoto, T; Ishida, T; Kagawa, Y; Kato, T; Katsura, Y; Kimura, K; Kuroda, Y; Kusama, H; Matsushita, K; Morimoto, Y; Nakahira, S; Nakatsuka, S; Nitta, K; Ohmura, Y; Ohzono, K; Okishiro, M; Sakisaka, H; Sato, Y; Takeda, Y; Takeno, A; Tamura, S; Taniguchi, H | 1 |
| Hata, T; Ishizu, H; Kuji, M; Masuko, H; Matsumoto, S; Tahara, M; Takahashi, H; Takahashi, M; Takahashi, S; Tanaka, K; Tanioka, T; Ueki, S; Yamagami, H | 1 |
| Doki, Y; Kurokawa, Y; Miyata, H; Miyazaki, Y; Mori, M; Nakajima, K; Nakatsuka, R; Takahashi, T; Takiguchi, S; Yamasaki, M | 1 |
| Akahane, D; Asano, M; Fujimoto, H; Gotoh, M; Ito, Y; Katagiri, S; Kitahara, T; Ohyashiki, JH; Ohyashiki, K; Okabe, S; Saito, Y; Suguro, T; Tanaka, Y; Tauchi, T; Umezu, T; Yoshizawa, S | 1 |
| Boer, JM; Cornelissen, JJ; den Boer, ML; Exalto, C; Koenders, JE; Rijneveld, AW; Sanders, MA; Valk, PJ; van der Holt, B | 1 |
| Baird, K; Booher, S; Comis, LE; Cowen, EW; Figg, WD; Flanders, KC; Hakim, FT; Joe, GO; Mitchell, SA; Pavletic, SZ; Rose, JJ; Sarantopoulos, S; Steinberg, SM; Takebe, N; Yao, L | 1 |
| Ai, HS; Qaio, JH; Zhang, ZC | 1 |
| Ainsworth, P; Carter, R; Dyck, J; Harvey, M; Hillis, C; Leber, B; Lin, HX; Pare, G; Sadikovic, B; Sjaarda, J; Stringer, R | 1 |
| Abruzzese, E; Assouline, S; Crivori, P; D'Emilio, A; De Riso, G; Elena, C; Gambacorti-Passerini, C; Giraldo, P; Gozzini, A; Iurlo, A; Kim, DW; le Coutre, P; Lodolo D'Oria, A; Luciani, M; Martino, B; Mezzatesta, C; Mori, S; Petroccione, A; Piazza, R; Pierri, I; Pirola, A; Pungolino, E; Redaelli, S; Stagno, F; Vagge, E | 1 |
| Bae, SH; Chi, HS; Eom, HS; Hyun, MS; Jang, DY; Joo, YD; Jung, CW; Kim, DY; Kim, H; Kim, HJ; Kim, I; Kim, MK; Lee, GW; Lee, JH; Lee, KH; Lee, SM; Lee, WS; Lim, SN; Moon, JH; Park, S; Ryoo, HM; Shin, HJ; Sohn, SK; Won, JH; Yang, DH; Yun, SC | 1 |
| Helbig, G; Hus, M; Kyrcz-Krzemień, S; Soja, A; Świderska, A | 1 |
| Bao, L; Chen, H; Huang, X; Jia, J; Jiang, B; Jiang, H; Jiang, Q; Liu, K; Lu, J; Wang, J; Xu, L; Yang, S; Zhang, X; Zhao, T; Zhu, H | 1 |
| Alberti, L; Blay, JY; Brahmi, M; Cassier, P; Decouvelaere, AV; Dufresne, A; Meeus, P; Ranchère-Vince, D; Ray-Coquard, I | 1 |
| Cho, EH; Jeon, SY; Kim, HS; Kim, JA; Kwak, JY; Lee, B; Lee, NR; Song, EK; Yhim, HY; Yim, CY | 1 |
| Abla, O; Weitzman, S | 1 |
| Gao, XN; Guo, YL; Han, XP; Jin, XS; Jing, Y; Liu, K; Yao, ZL; Yu, L; Zhang, R | 1 |
| Doki, N; Fujiwara, T; Kakihana, K; Kobayashi, T; Narukawa, K; Ohashi, K; Sakamaki, H | 1 |
| Chang, MH; Choi, MY; Choi, SY; Do, YR; Kim, DW; Kim, DY; Kim, H; Kim, HJ; Kim, JA; Kim, SH; Kwak, JY; Kwon, JH; Lee, SE; Lee, WS; Mun, YC; Oh, S; Park, J; Park, JS; Song, HY; Zang, DY | 1 |
| Aguzzi, C; Boccadoro, M; Cerrano, M; Crisà, E; Ferrero, D; Giai, V | 1 |
| Attarbaschi, A; Haas, OA; König, M; Lackner, H; Mann, G; Panzer-Grümayer, R; Perwein, T; Strehl, S; Urban, EC | 1 |
| Angelucci, E; Audisio, E; Bassan, R; Borlenghi, E; Boschini, C; Cattaneo, C; Cavattoni, IM; Ciceri, F; Cortelezzi, A; Gianni, F; Grassi, A; Intermesoli, T; Lussana, F; Mannelli, F; Masciulli, A; Mattei, D; Oldani, E; Parolini, M; Raimondi, R; Rambaldi, A; Romani, C; Scattolin, AM; Spinelli, O; Terruzzi, E; Tosi, M | 1 |
| Califano, C; Chiaretti, S; De Fabritiis, P; Dore, F; Elia, L; Falini, B; Fanin, R; Fazi, P; Ferrara, F; Foà, R; La Nasa, G; Luppi, M; Mandelli, F; Meloni, G; Piciocchi, A; Ronco, F; Tedeschi, A; Vignetti, M; Vitale, A | 1 |
| Carré, M; Charbonnier, A; Dubruille, V; Etienne, G; Gardembas, M; Guerci-Bresler, A; Guilhot, F; Guilhot, J; Ianotto, JC; Legros, L; Mahon, FX; Nicolini, F; Noel, MP; Rea, D; Rigal-Huguet, F; Rousselot, P; Tulliez, M; Varet, B; Villemagne, B | 1 |
| Akiyama, H; Aoyama, Y; Dobashi, N; Fujisawa, S; Hatta, Y; Imai, K; Kakihana, K; Maeda, T; Matsuo, K; Miyazaki, Y; Mizuta, S; Naoe, T; Ohnishi, K; Ohtake, S; Onishi, Y; Sugiura, I; Ueda, Y | 1 |
| Ishizaki, M; Katoh, T; Komine, C; Matsumoto, A; Morinaga, N; Nakamura, T; Nakazato, K; Saito, H; Shitara, Y; Tanaka, N | 1 |
| Abboud, C; Becker, M; Friedberg, J; Ifthikharuddin, J; Komrokji, RS; Liesveld, JL; Messina, P; Mulford, D; Oliva, J; Phillips, G; Walker, AR | 1 |
| Hughes, TP; Ross, DM | 1 |
| Breeden, M; Cortes, JE; Giles, FJ; Jabbour, E; Jones, D; Kantarjian, HM; O'Brien, S; Thomas, D; Yin, CC; Zhao, W | 1 |
| Baldridge, LA; Breen, T; Emerson, RE; Johnson, CS; Matei, D; McClean, J; Menning, N; Schilder, J; Stephens, D; Sutton, G; Whalen, C | 1 |
| Chen, S; Huang, X; Jiang, B; Jiang, H; Jiang, Q; Li, J; Li, L; Liu, Y; Qin, Y; Zhang, Y; Zhu, H | 1 |
| Ohno, R | 1 |
| Abou Mourad, YR; Fernandez, HF; Kharfan-Dabaja, MA | 1 |
| Suttorp, M | 1 |
| Akiyama, H; Jinnai, I; Kimura, Y; Maruta, A; Matsuo, K; Miyawaki, S; Miyazaki, Y; Naoe, T; Narimatsu, H; Nishii, K; Ohno, R; Ohtake, S; Sugiura, I; Takeuchi, J; Takeuchi, M; Ueda, Y; Usui, N; Yagasaki, F; Yanada, M; Yujiri, T | 1 |
| Alimena, G; Breccia, M; Cannella, L; Cilloni, D; Fama, A; Saglio, G; Santopietro, M; Stefanizzi, C; Tafuri, A | 1 |
| Chung, NG; Kim, CC; Kim, HJ; Kim, YJ; Lee, DG; Lee, JW; Lee, S; Lim, J; Min, CK; Min, WS | 1 |
| Auclerc, MF; Baruchel, A; Cayuela, JM; Chevret, S; Debre, M; Demeocq, F; Gandemer, V; Jonveaux, P; Le Gall, E; Lejars, O; Leverger, G; Perel, Y; Piguet, C; Schmitt, C; Stephan, JL; Vannier, JP | 1 |
| Höffken, K; Lemm, D; Mentzel, T; Mügge, LO | 1 |
| Kiguchi, T; Ohyashiki, K; Tauchi, T | 1 |
| Beumer, JH; Desjardins, A; Egorin, MJ; Friedman, HS; Gururangan, S; Herndon, JE; Lagattuta, TF; Reardon, DA; Salvado, AJ; Vredenburgh, JJ | 1 |
| Ayuk, F; Bacher, U; Brümmendorf, TH; Fiedler, W; Hochhaus, A; Iwanski, GB; Klyuchnikov, E; Kröger, N; Ocheni, S; Schafhausen, P; Schnittger, S; Zabelina, T; Zander, AR | 1 |
| Bensimhon, D; Boudiaf, M; Dray, X; Duchat, F; Fargeaudou, Y; Hamzi, L; Idy-Peretti, I; Martin-Grivaud, S; Nemeth, J; Pocard, M; Rymer, R; Soyer, P | 1 |
| Abruzzese, E; Amabile, M; Baccarani, M; Castagnetti, F; Cilloni, D; Colarossi, S; de Matteis, S; Gnani, A; Gozzini, A; Gugliotta, G; Iacobucci, I; Martinelli, G; Merante, S; Orlandi, E; Palandri, F; Paolini, S; Papayannidis, C; Poerio, A; Rosti, G; Soverini, S | 1 |
| Arias-Bonfill, D; Candelaria, M; Cantú, D; Chanona, J; Chávez-Blanco, A; Dueñas-González, A; Pérez, C | 1 |
| Abe, A; Emi, N; Hayakawa, F; Imagama, S; Ito, Y; Katsumi, A; Kiyoi, H; Minami, Y; Naoe, T; Nomura, Y; Suzuki, M; Tanizaki, R; Yamamoto, K | 1 |
| Barozzi, P; Basso, S; Comoli, P; D'Amico, R; Del Giovane, C; Forghieri, F; Locatelli, F; Luppi, M; Maccaferri, M; Morselli, M; Potenza, L; Quadrelli, C; Riva, G; Torelli, G; Vallerini, D; Volzone, F; Zanetti, E | 1 |
| Hasegawa, M; Ishikawa, O; Kuraishi, N; Nagai, Y | 1 |
| Liu, X; Lu, X; Song, X; Wang, J; Wang, L; Ye, Y; Ying, B; Zhang, L; Zhou, Y | 1 |
| Deng, D; Lai, Y; Li, Q; Liang, Y; Liu, R; Luo, J; Ma, J; Peng, Z; Schwarzenberger, P; Shi, L; Yang, J; Zhou, J; Zhou, Y | 1 |
| Oehler, VG; Radich, JP | 2 |
| Cortes, J; Kantarjian, H; O'Brien, S; Thomas, DA | 1 |
| Advani, AS; Bates, J; Copelan, EA; Cotta, CV; Egorin, MJ; Howard, M; Hsi, E; Jin, T; Kalaycio, M; Lim, K; Maciejewski, J; Noon, E; Price, C; Rush, ML; Salvado, A; Saunthararajah, Y; Sekeres, MA; Sobecks, R; Tiu, R; Tripp, B | 1 |
| Chun, JM; Hwang, YJ; Jin, R; Kim, JY; Kim, SG; Won, DI | 1 |
| Eapen, M | 1 |
| Boehm, A; Dieckmann, K; Fischer, G; Greinix, HT; Haas, OA; Hinterberger, W; Kalhs, P; Lechner, K; Mitterbauer, G; Mitterbauer, M; Pernicka, E; Rabitsch, W; Rosenmayr, A; Schwarzinger, I; Sperr, WR; Valent, P; Walcherberger, B; Wöhrer, S; Worel, N | 1 |
| Baldini, L; F, FG; Ferrario, A; Goldaniga, M; Olivero, B; Radaelli, F; Rossi, F | 1 |
| Blay, JY; Brain, EG; Bui, BN; Chabaud, S; Chevreau, C; Cupissol, D; Duffaud, F; Guillemet, C; Jimenez, M; Le Cesne, A; Mignot, L; Penel, N; Perol, D; Piperno-Neumann, S; Ray-Coquard, I | 1 |
| Blackstein, ME; Blay, JY; von Mehren, M | 1 |
| Chen, SS; Huang, XJ; Jiang, B; Jiang, H; Jiang, Q; Lai, YY; Qin, YZ | 1 |
| Al-Shehri, A; Belgaumi, AF | 1 |
| Aglietta, M; Boglione, A; Casali, PG; Comandone, A; Ferraresi, V; Ferrari, S; Frustaci, S; Grignani, G; Palmerini, E; Stacchiotti, S | 1 |
| Valent, P | 1 |
| Charbonnier, A; Etienne, G; Guerci, A; Guilhot, F; Guilhot, J; Huguet, F; Legros, L; Mahon, FX; Nicolini, F; Réa, D; Reiffers, J; Rousselot, P; Varet, B | 1 |
| Choi, D; Kang, HJ; Kang, YK; Kim, KM; Kim, WH; Ryu, MH; Sohn, T; Yang, HK | 1 |
| Gratwohl, A; Heim, D | 1 |
| Hauswirth, F; Jäger, D; Jungbluth, A; Metzger, U; Perez, D; Samartzis, EP; Went, P | 1 |
| Alimena, G; Breccia, M; Cannella, L; De Propris, MS; Diverio, D; Federico, V; Loglisci, G; Nanni, M; Petrucci, L; Salaroli, A; Santopietro, M; Serrao, A | 1 |
| Bouvresse, S; Clérici, T; de Masson, A; Mahé, E; Saïag, P | 1 |
| Fujisawa, S; Fujita, H; Ishigatsubo, Y; Kanamori, H; Maruta, A; Motohashi, K; Numata, A; Sakai, R; Tachibana, T; Tanaka, M; Tomita, N | 1 |
| Bachmeyer, C; Garandeau, E; Lecomte, I; Lionnet, F; Stankovic Stojanovic, K; Thiolière, B | 1 |
| Chauncey, TR; Flowers, ME; Georges, GE; Lange, T; Langston, AA; Laport, GG; Maloney, DG; Maris, MB; Ram, R; Sandmaier, BM; Storb, R; Storer, B; Woolfrey, A | 1 |
| Nishida, T; Omori, T; Ueshima, S | 1 |
| Dumon-Gubeno, MC; Figueredo, M; Medioni, LD; Mouroux, J; Naman, H; Nicolle, I; Tarhini, A; Vandenbos, F | 1 |
| Chollet, C; Costaglioli, P; Dupouy, M; Etienne, G; Garbay, B; Lagarde, V; Mahon, FX; Pasquet, JM; Reiffers, J; Turcq, B | 1 |
| Arqueros, V; Martín-Palanco, V; Martínez, F; Román-Gómez, J; Torres, A | 1 |
| Chaudhry, UI; DeMatteo, RP | 1 |
| Ahmadzadeh, A; Charoosaei, R; Haybar, H; Jalaeikhoo, H; Keyhani, M; Toogeh, G; Valizadeh, A; Yadollahzadeh, M | 1 |
| Boku, N; Doi, T; Hirota, S; Kakeji, Y; Kanda, T; Katai, H; Kikuchi, S; Kobayashi, O; Komatsu, Y; Koseki, M; Miyachi, K; Nishida, T; Ogoshi, K; Ohtsu, A; Sawaki, A; Sugiyama, T; Toh, Y; Wada, N; Yamamoto, M | 1 |
| Kawaguchi, T; Kitamura, K; Kyo, T; Maeda, Y; Motoji, T; Ohe, Y; Ohtake, S; Ohyashiki, K; Okamoto, S; Sawada, K; Sugihara, T; Takahashi, N; Tamaki, T; Teshima, H; Usui, N; Usuki, K; Yamamoto, M | 1 |
| Andtbacka, RH; Benjamin, RS; Cano, P; Chan, BK; Chen, LC; Chen, LL; Chen, X; Choi, H; Frazier, ML; Gouw, L; Hill, HR; Jensen, P; Jimenez, A; Jones, KA; Lazar, AJ; Lin, P; Martins, T; Morton, K; Oyedeji, CO; Patel, S; Randall, RL; Rodesch, CK; Sang, H; Scaife, CL; Schumacher, J; Trent, JC; Ward, JH; Willmore, C; Zhang, H | 1 |
| Chika, N; Kakimoto, M; Kikuchi, A; Koshiishi, H; Nishida, K; Okamura, T; Tokita, H; Yoshimura, T | 1 |
| Cantú-Rodríguez, O; García-Rodríguez, F; Gómez-Almaguer, D; González-Llano, O; Gutiérrez-Aguirre, H; Jaime-Pérez, J | 1 |
| Camitta, BM; Carroll, WL; Chang, BH; Druker, BJ; Hunger, SP; Schultz, KR; Stork, L; Willis, SG; Winick, NJ | 1 |
| Foo, J; Gönen, M; Guilhot, J; Mahon, FX; Michor, F; Tang, M | 1 |
| Bang, JH; Branford, S; Choi, SY; Hughes, TP; Kim, DW; Park, JE; Prime, JA; Ross, DM; Yeung, DT | 1 |
| Hayashi, T; Igarashi, T; Ikeda, H; Ishida, T; Shinomura, Y; Takahashi, T; Yasui, H | 1 |
| Biasco, G; Nannini, M; Pantaleo, MA; Saponara, M | 1 |
| Bhatt, VR; Gupta, S; Varma, S | 1 |
| Appelbaum, FR; Deininger, M; Druker, BJ; Emanuel, P; Kamel-Reid, S; Kopecky, KJ; Larson, RA; Lipton, J; Malnassy, G; Paietta, E; Radich, JP; Stock, W; Tallman, M; Turner, AR; Wadleigh, M | 1 |
| Giraudier, S; Huguet, F; Legros, L; Mahon, FX; Nicolini, FE; Rousselot, P; Tulliez, M | 1 |
| Alpár, D; de Jong, D; Kajtár, B; Kereskai, L; Pajor, L; Savola, S; Szuhai, K; Yigittop, H | 1 |
| Alimena, G; Breccia, M | 1 |
| Katagiri, S; Ohyashiki, JH; Ohyashiki, K; Umezu, T | 1 |
| Ikehara, T; Inoue, T; Kanehara, I; Nishiguchi, Y; Sakashita, K; Shimizu, S; Teraoka, H; Toyokawa, T; Yamamoto, A; Yamashita, Y | 1 |
| Branford, S | 1 |
| Mahon, FX | 1 |
| Posner, MC; Roggin, KK | 1 |
| Akasaka, H; Hakamada, K; Koyama, M; Morohashi, H; Murata, A; Sakamoto, Y; Yokoyama, H | 1 |
| Funaki, H; Kaida, D; Kinami, S; Kosaka, T; Minato, H; Morioka, E; Nakano, Y; Nakata, S; Noguchi, M; Ohnishi, T; Ohno, Y; Omote, K; Takamura, H; Tomita, Y; Ueda, N | 1 |
| Fan, ZP; Huang, F; Jiang, QL; Ling, YW; Liu, QF; Sun, J; Zhai, X; Zhang, FH; Zhang, Y; Zhou, HS | 1 |
| Arlinghaus, R; Champlin, R; Cortes, JE; De Lima, M; Faderl, S; Garcia-Manero, G; Giles, FJ; Giralt, SA; Kantarjian, HM; O'Brien, S; Rios, MB; Shan, J; Talpaz, M; Thomas, DA | 1 |
| Berger, U; Gschaidmeier, H; Hehlmann, R; Hochhaus, A; Kreil, S; Kuhn, C; Lahaye, T; Merx, K; Müller, MC; Paschka, P; Schoch, C; Weisser, A | 1 |
| Gorre, ME; Kuriyan, J; Nagar, B; Nicoll, JM; Paquette, RL; Sawyers, CL; Shah, NP | 1 |
| Antonescu, CR; Awan, RA; Dixon, RH; Jhanwar, S; Maki, RG | 1 |
| Alberti, D; Amabile, M; Baccarani, M; Capdeville, R; Guiducci, B; Isidori, A; Malagola, M; Martinelli, G; Piccaluga, PP; Tura, S; Visani, G | 1 |
| Au, WY; Chan, EC; Kwong, YL; Liang, R; Lie, AK; Ma, SK; Wan, TS | 1 |
| Breitenbuecher, F; Fischer, T; Gamm, H; Gschaidmeier, H; Hess, G; Huber, C; Kindler, T; Kirkpatrick, CJ; Marx, A | 1 |
| Druker, BJ | 1 |
| Conneally, E; Gately, K; Lawler, M; McCann, SR | 1 |
| Arlinghaus, R; Cortes, J; Faderl, S; Giles, F; Kantarjian, HM; O'Brien, S; Rios, MB; Shan, J; Talpaz, M; Thomas, D | 1 |
| Corbin, AS; Deininger, MW; Druker, BJ; La Rosée, P; Stoffregen, EP | 1 |
| Apperley, JF; Bua, M; Foot, N; Goldman, JM; Marin, D; Marktel, S | 1 |
| Ottmann, OG; Wassmann, B | 1 |
| Bornhäuser, M; Griesinger, F; Gschaidmeier, H; Hochhaus, A; Hoelzer, D; Ottmann, OG; Pfeifer, H; Scheuring, U; Schleyer, E; Thiede, C; Wassmann, B | 1 |
| Albitar, M; Cortes, J; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, H; Letvak, L; O'Brien, S; Rios, MB; Salvado, A; Talpaz, M; Thomas, D | 1 |
| Amaral, SM; Boulton, CL; Cools, J; Coutre, SE; Curley, DP; DeAngelo, DJ; Duclos, N; Fabbro, D; Gilliland, DG; Gotlib, J; Griffin, JD; Kutok, JL; Lee, BH; Legare, RD; Manley, PW; Marynen, P; Meyer, T; Neuberg, D; Rowan, R; Stone, RM; Stover, EH; Weisberg, E; Williams, IR | 1 |
| Briesewitz, R; Bruner, RJ; Caligiuri, MA; Griffin, JH; Leung, J | 1 |
| Ahlgren, T; Barbouti, A; Fioretos, T; Höglund, M; Johansson, B; Lassen, C; Mitelman, F; Turesson, I | 1 |
| Baskaynak, G; Ehninger, G; Gschaidmeier, H; Holdhoff, M; Huhn, D; Kreuzer, KA; Le Coutre, P; Lupberger, J; Na, IK; Platzbecker, U; Prejzner, W; Schmidt, CA; Schwarz, M | 1 |
| Häyry, P; Savikko, J; Von Willebrand, E | 1 |
| Blasdel, C; Druker, BJ; Farnsworth, M; Hsieh, YC; Kurilik, G; Mauro, MJ; Mori, M; O'Dwyer, ME | 1 |
| Aulitzky, W; Berger, U; Berndt, A; Deininger, MW; Fischer, T; Freund, M; Fruehauf, S; Gattermann, N; Gschaidmeier, H; Hehlmann, R; Hochhaus, A; Hossfeld, DK; König, H; Krause, SW; Kreil, S; Lahaye, T; le Coutre, P; Merx, K; Müller, MC; Nerl, C; Neubauer, A; Ottmann, OG; Paschka, P; Sayer, HG; Schneller, F; Waller, C | 1 |
| Fischer, T; Friedrich-Freksa, A; Gschaidmeier, H; Hess, G; Huber, C; Kolbe, K; Meyer, RG; Ullmann, AJ | 1 |
| Atta, J; Binckebanck, A; Brück, P; Ehninger, G; Gökbuget, N; Gschaidmeier, H; Hoelzer, D; Leimer, L; Lipp, T; Ottmann, OG; Perz, J; Pfeifer, H; Rieder, H; Scheuring, UJ; Schoch, C; Schwerdtfeger, R; Stelljes, M; Wassmann, B | 1 |
| Jin Huh, H; Lee, M; Myong Seong, C; Soon Chung, W; Won Huh, J | 1 |
| Hwang, JY; Kim, CC; Kim, DW; Kim, HJ; Kim, YJ; Kim, YL; Lee, JW; Lee, S; Min, WS; Park, YH | 1 |
| Alberti, D; Amabile, M; Baccarani, M; Bassi, S; Bonifazi, F; Cambrin, GR; Cilloni, D; De Vivo, A; Giannini, B; Gottardi, E; Izzo, B; Luatti, S; Martinelli, G; Pane, F; Rosti, G; Saglio, G; Salvatore, F; Soverini, S; Testoni, N; Trabacchi, E | 1 |
| Bourgeois, E; Cambier, N; Dupire, S; Grardel, N; Preudhomme, C; Roche-Lestienne, C; Rose, C | 1 |
| Chung, NG; Hwang, JY; Kim, CC; Kim, DW; Kim, YJ; Kim, YL; Lee, S; Min, CK | 1 |
| Bloomfield, CD; Carroll, AJ; Dodge, RK; Larson, RA; Mrózek, K; Stewart, CC; Tantravahi, R; Vardiman, JW; Wetzler, M | 1 |
| Al-Ali, HK; Deininger, MW; Druker, BJ; Heinrich, MC; Krahl, R; Lange, T; Mueller, M; Müller, C; Niederwieser, D | 1 |
| Druker, BJ; Mauro, MJ; Maziarz, RT | 1 |
| Bujassoum, S; Lipton, JH; Rifkind, J | 1 |
| Chiyonobu, T; Imamura, T; Imashuku, S; Ishida, H; Morimoto, A; Ogami, A; Sugimoto, T; Takanashi, M; Yoshihara, T | 1 |
| Curtin, PT; Druker, BJ; Ford, JM; Leis, JF; Maziarz, RT; Peng, B; Schubach, S; Stepan, DE | 1 |
| Borthakur, G; Cortes, JE | 1 |
| Sato, Y; Tanizawa, Y; Yujiri, T | 1 |
| Alyea, EP; Antin, JH; DeAngelo, DJ; Galinsky, I; Hochberg, EP; Lee, S; Longtine, J; Parekkedon, B; Ritz, J; Soiffer, RJ; Stone, RM | 1 |
| Agis, H; Geissler, K; Haas, OA; Kalhs, P; Keil, F; Krauth, MT; Lechner, K; Mannhalter, C; Pirc-Danoewinata, H; Sperr, WR; Valent, P | 1 |
| Pulsipher, MA | 1 |
| Goh, HG; Kim, CC; Kim, DW; Kim, HJ; Kim, SH; Kim, TG; Kim, YJ; Kim, YL; Lee, JW; Lee, JY; Lee, S; Min, CK; Min, WS | 1 |
| Blay, JY; Bompas, E; Velay, B | 1 |
| Anderlini, P; Champlin, RE; Giralt, S; Hicks, K; Ippoliti, C; Sheth, S | 1 |
| Cai, CC; Hong, WD; Li, J; Li, QH; Li, XH; Luo, SK; Peng, AH; Tan, EX; Tong, XZ; Zhang, GC; Zheng, D | 1 |
| Iijima, K; Iki, S; Urabe, A; Usuki, K | 1 |
| Chang, TM; Chen, TW; Hsieh, CB; Liu, HD; Shih, ML; Shyu, RY; Yu, JC | 1 |
| Eom, KS; Kim, CC; Kim, DW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Min, CK; Min, WS | 1 |
| Andreasson, C; Apperley, JF; Bua, M; Dazzi, F; Fleming, A; Goldman, JM; Howard, J; Kaeda, J; Kanfer, E; Marin, D; Olavarria, E; Rahemtulla, A; Saunders, S; Szydlo, R | 1 |
| Deininger, MW; Druker, BJ; O'Hare, T; Walters, DK | 1 |
| Chehal, A; El Hajj, II; El Saghir, NS | 1 |
| Basara, N; Binckebanck, A; Bornhaüser, M; Brück, P; Bug, G; Bunjes, D; Gschaidmeier, H; Hoelzer, D; Ledderose, G; Mahlberg, R; Ottmann, OG; Perz, J; Pfeifer, H; Scheuring, UJ; Schwerdtfeger, R; Stadler, M; Stelljes, M; Wassmann, B | 1 |
| Fukushima-Nakase, Y; Harada, H; Imashuku, S; Kakazu, N; Kuroda, H; Morimoto, A; Tamura, S; Teramura, T; Ueda, I | 1 |
| Ali, R; Gülten, T; Kimya, Y; Köksal, N; Ozan, U; Ozçelik, T; Ozkalemkaş, F; Ozkocaman, V; Tunali, A; Yakut, T | 1 |
| Biondi, A; Colnaghi, F; Dassi, M; Elli, E; Fumagalli, M; Gambacorti-Passerini, C; Giudici, G; Parma, M; Perseghin, P; Pioltelli, P; Pogliani, EM; Ponchio, L; Tornaghi, L | 1 |
| Gilliland, DG; Huntly, BJ | 1 |
| Branford, S; Hughes, TP; Iwasa, Y; Michor, F; Nowak, MA; Sawyers, CL; Shah, NP | 1 |
| Bernasconi, P; Boni, M; Calatroni, S; Lazzarino, M; Merante, S; Orlandi, E | 1 |
| Fox, C; Russell, NH; Stergianou, K | 1 |
| Caplan, SN; Fetni, R; Johnson, NA | 1 |
| Asou, N; Kawakita, T; Matsuno, N; Mitsuya, H; Nanri, T | 1 |
| Barrett, AJ; Childs, R; Hensel, N; Kurlander, R; Montero, A; Savani, BN | 1 |
| Cavenagh, J; Clark, RE; Cummins, M; Cwynarski, K; Dazzi, F; Holyoake, TL; Marks, DI; Marktel, S; Milligan, D; Parker, A; Russell, NH | 1 |
| Allred, J; Dispenzieri, A; Fonseca, R; Gertz, MA; Geyer, SM; Greipp, PR; Kimlinger, T; Lacy, MQ; Lust, JA; Rajkumar, SV; Witzig, TE | 1 |
| Békassy, AN; De Bont, ES; Gadner, H; Gschaidmeier, H; Guilhot, F; Guilhot, J; Leblanc, T; Millot, F; Nelken, B; Stary, J; Sufliarska, S; Suttorp, M | 1 |
| Bornhäuser, M; Ehninger, G; Fruehauf, S; Kiehl, MG; Kienast, J; Kröger, N; Mundhenk, P; Sayer, HG; Schafer-Eckart, K; Scheid, C; Schwerdtfeger, R; Stelljes, M; Theuser, C; Wandt, H; Zander, AR | 1 |
| Butterfield, JH; Camoriano, JK; Dewald, GW; Elliott, MA; Ketterling, RP; Li, CY; Pardanani, A; Patnaik, MM; Tefferi, A; Wolanskyj, AP | 1 |
| Charlanne, H; Prin, L | 1 |
| Dai, H; Druker, B; Friend, S; Linsley, PS; Mao, M; Oehler, V; Radich, JP; Sawyers, C; Schelter, J; Shah, N; Stock, W; Willman, CL | 1 |
| Christen, S; Friess, D; Gratwohl, A; Heim, D; Meyer-Monard, S; Passweg, JR; Stüssi, G; Tichelli, A | 1 |
| Andersson, BS; Champlin, R; Cortes, J; de Lima, M; Giles, F; Giralt, S; Jabbour, E; Jones, D; Jones, R; Kantarjian, HM | 1 |
| Kolb, HJ; Ledderose, G; Schnittger, S; Schoch, C; Tischer, J; Weisser, M | 1 |
| Alimena, G; Biondo, F; Breccia, M; Diverio, D; Frustaci, A; Gentilini, F; Nanni, M; Pane, F; Russo, E | 1 |
| Bustamante Z, M; Capetillo Fuentes, M; Carvajal H, C; Contreras P, JE; Iturra U, S; Justiniano P, JC; Lombardi S, J | 1 |
| Selleslag, D | 1 |
| Au, WY; Chan, E; Lie, AK | 1 |
| Blanchet, O; Cayuela, JM; Gardembas, M; Gluckman, E; Huguet, F; Legros, L; Maarek, O; Mahon, FX; Marit, G; Rea, D; Reiffers, J; Rousselot, P | 1 |
| Wodarz, D | 1 |
| Amabile, M; Angelucci, E; Baccarani, M; Bandini, G; Benedetti, F; Fanin, R; Martinelli, G; Palandri, F; Rosti, G; Tiribelli, M; Usala, E | 1 |
| Bunjes, D; Döhner, H; Döhner, K; Greiner, J; Harsdorf, Sv; Marx, M; Ringhoffer, M; Schmitt, M; Stilgenbauer, S; Wiesneth, M; Zenz, T | 1 |
| Kumar, R; Mahapatra, M; Mishra, P | 1 |
| Banerjee, A; Blaney, SM; Boyett, JM; Friedman, H; Geyer, JR; Goldman, S; Hancock, ML; Hayes, M; Jakacki, RI; Kieran, MW; Krasin, MJ; Kun, LE; Murgo, A; Packer, R; Phillips, P; Pollack, IF; Poussaint, TY; Wang, Y; Weiner, S | 1 |
| Hoshino, T; Isoda, A; Mitsui, T; Nakahashi, H; Yoshida, Y | 1 |
| Chun, K; Kamel-Reid, S; Lipton, J; Medeiros, BC | 1 |
| Baccarani, M; Bosi, C; Castagnetti, F; Cilloni, D; Colarossi, S; Giannoulia, P; Gnani, A; Iacobucci, I; Luatti, S; Martinelli, G; Marzocchi, G; Palandri, F; Paolini, S; Piccaluga, PP; Rondoni, M; Rosti, G; Saglio, G; Soverini, S; Testoni, N | 1 |
| Chen, H; Han, W; Huang, XJ; Liu, DH; Liu, KY; Xu, LP | 1 |
| Barbu, V; Carbonne, B; Garderet, L; Gorin, NC; Santacruz, R; van den Akker, J | 1 |
| Binckebanck, A; Brück, P; Hochhaus, A; Hoelzer, D; Lange, T; Oldenburg, J; Ottmann, OG; Pavlova, A; Pfeifer, H; Wassmann, B; Wunderle, L; Wystub, S | 1 |
| Apperley, JF; Chaidos, A; Kanfer, E | 1 |
| Benjamin, RS; Burgess, MA; Charnsangavej, C; Chen, LL; Choi, H; Macapinlac, HA; Patel, SR; Podoloff, DA | 1 |
| Deininger, MW; Eide, CA; O'Hare, T | 1 |
| Ambudkar, SV; Bates, SE; Boudriot, U; Brendel, C; Burchert, A; Dohse, M; Neubauer, A; Robey, RW; Scharenberg, C; Shukla, S; Wang, Y; Wennemuth, G | 1 |
| Ahlman, H; Andersson, J; Bümming, P; Kindblom, LG; Meis-Kindblom, JM; Nilsson, B; Nilsson, O; Sjölund, K | 1 |
| Griffin, MO; Guttormsen, B; Hacker, TA; Stoker, S; Wolff, MR | 1 |
| Belaud-Rotureau, MA; Bouabdallah, K; Fitoussi, O; Foucaud, C; Leguay, T; Marit, G; Milpied, N; Parrens, M; Pigneux, A; Tabrizi, R | 1 |
| Hishida, A; Katagiri, T; Nakamura, Y; Naoe, T; Ohno, R; Sugiura, I; Takeuchi, J; Tsuruo, T; Usui, N; Yanada, M; Zembutsu, H | 1 |
| Araki, H; Araki, N; Fujimi, A; Hirayama, Y; Kato, J; Kogawa, K; Matsunaga, T; Murase, K; Niitsu, Y; Takahira, N; Takimoto, R; Terui, T | 1 |
| Martinelli, G; Paolini, S; Piccaluga, PP | 1 |
| Dunbar, CE; Fay, MP; Fu, W; Hartsell, M; Klion, AD; Law, MA; Lemery, S; Maric, I; Noel, P; Nutman, TB; Robyn, J; Schmid, L; Talar-Williams, C | 1 |
| Bock, O; Buesche, G; Frye, B; Gadzicki, D; Ganser, A; Hecker, H; Kreipe, H; Schlegelberger, B; von Neuhoff, N | 1 |
| Brodzik, F; Mehdi, S; Pasquale, D; Ramanarayanan, J | 1 |
| Chiusolo, P; Farina, G; Fiorini, A; Leone, G; Reddiconto, G; Sica, S; Sorà, F | 1 |
| Graiff, C; Mazzoleni, G; Pedersini, R; Vattemi, E | 1 |
| Bruguera, M; Fuster, F; Granell, M; Medina, L; Vallansot, R | 1 |
| Cross, SA; Lyseng-Williamson, KA | 1 |
| Wassmann, B | 1 |
| Swords, R | 1 |
| Brandwein, J | 1 |
| Fairman, P; Grinnan, DC; Pinson, J | 1 |
| Erben, P; Ernst, T; Hehlmann, R; Hochhaus, A; Hoffmann, J; Kreil, S; La Rosée, P; Müller, MC; Paschka, P; Schenk, T | 1 |
| Akiyama, H; Jinnai, I; Maruta, A; Matsuo, K; Miyawaki, S; Miyazaki, Y; Naoe, T; Narimatsu, H; Nishii, K; Ohno, R; Ohtake, S; Sugiura, I; Takeuchi, J; Takeuchi, M; Ueda, Y; Usui, N; Yagasaki, F; Yanada, M | 1 |
| Baccarani, M; Pane, F; Saglio, G | 1 |
| England, RW; Scranton, SE; Wild, CA | 1 |
| Buttignol, S; Candoni, A; Fanin, R; Simeone, E; Sperotto, A; Tiribelli, M | 1 |
| Buchdunger, E; Capdeville, R; Druker, BJ; Ford, JM; Kantarjian, H; Lydon, NB; Ohno-Jones, S; Peng, B; Resta, DJ; Sawyers, CL; Talpaz, M | 1 |
| Capdeville, R; Druker, BJ; Ford, JM; Kantarjian, H; Reese, SF; Resta, DJ; Sawyers, CL; Talpaz, M | 1 |
| Goldman, JM; Mughal, TI | 1 |
| Ellwood, K; Gorre, ME; Hsu, N; Mohammed, M; Paquette, R; Rao, PN; Sawyers, CL | 1 |
| McCormick, F | 1 |
| Sawyers, CL | 1 |
| Baron, F; Beguin, Y; Fillet, G; Frère, P | 1 |
| Jeanteur, P | 1 |
| Schiffer, CA | 1 |
| Beran, M; Dong, L; Kantarjian, HM; Keating, MJ; Onida, F; Scappini, B; Verstovsek, S | 1 |
| Bown, N; Capdeville, R; Chang, J; Connors, S; Melo, JV; O'Brien, SG; Vieira, SA | 1 |
36 review(s) available for imatinib mesylate and Recrudescence
| Article | Year |
|---|---|
Second-Generation Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia Patients with Stable Deep Molecular Response: A Systematic Review and a Meta-Analysis.
Topics: Antineoplastic Agents; Computational Biology; Dasatinib; Disease-Free Survival; Duration of Therapy; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Remission Induction | 2021 |
A Systematic Review on Second Treatment-Free Remission (TFR) Attempt in Chronic Myeloid Leukemia (CML): Can it be Applied in Clinical Practice?
Topics: Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Quality of Life; Recurrence | 2023 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Disease-Free Survival; Drug Administration Schedule; Drug Monitoring; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Meta-Analysis as Topic; Musculoskeletal Pain; Observational Studies as Topic; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Recurrence; Remission Induction; RNA, Messenger; RNA, Neoplasm; Substance Withdrawal Syndrome; Withholding Treatment | 2020 |
Uncontrolled neovascular glaucoma - an alarming manifestation of chronic myeloid leukemia on imatinib therapy - a case report and review of literature.
Topics: Antineoplastic Agents; Glaucoma, Neovascular; Gonioscopy; Humans; Imatinib Mesylate; Intraocular Pressure; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Recurrence; Trabeculectomy; Visual Acuity | 2019 |
Current and future management of Ph/BCR-ABL positive ALL.
Topics: Age of Onset; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chromosome Aberrations; Clinical Trials as Topic; Cytogenetic Analysis; Disease Management; Drug Resistance, Neoplasm; Drugs, Investigational; Forecasting; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunophenotyping; Incidence; Molecular Targeted Therapy; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Treatment Outcome | 2014 |
[Long-term survival in a case of recurrent gastrointestinal stromal tumor treated with intermittent or low-dose imatinib].
Topics: Aged; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Recurrence; Stomach Neoplasms; Time Factors; Treatment Outcome | 2014 |
Treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Female; Humans; Imatinib Mesylate; Immunotherapy; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Remission Induction; Treatment Outcome | 2008 |
Allogeneic hematopoietic cell transplantation for adult Philadelphia-positive acute lymphoblastic leukemia in the era of tyrosine kinase inhibitors.
Topics: Adult; Algorithms; Benzamides; Disease-Free Survival; Glucocorticoids; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Remission Induction; Survival Rate; Transplantation, Homologous | 2008 |
Innovative approaches of targeted therapy for CML of childhood in combination with paediatric haematopoietic SCT.
Topics: Algorithms; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Clinical Trials as Topic; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Living Donors; Male; Monitoring, Physiologic; Piperazines; Pyrimidines; Recurrence; Transplantation, Homologous | 2008 |
Current treatment options in dermatofibrosarcoma protuberans.
Topics: Antineoplastic Agents; Benzamides; Cell Division; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Immunohistochemistry; Microsurgery; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Recurrence; Skin Neoplasms | 2009 |
Chronic myelogenous leukemia. Clinical practice guidelines in oncology.
Topics: Benzamides; Disease Progression; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Practice Guidelines as Topic; Pyrimidines; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Transplantation, Homologous | 2003 |
Lichenoid drug eruption with palmoplantar hyperkeratosis due to imatinib mesylate: a case report and a review of the literature.
Topics: Administration, Topical; Adrenal Cortex Hormones; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Dermatologic Agents; Dose-Response Relationship, Drug; Drug Eruptions; Female; Humans; Imatinib Mesylate; Keratoderma, Palmoplantar; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lichenoid Eruptions; Male; Middle Aged; Piperazines; Pyrimidines; Recurrence; Skin; Treatment Outcome | 2010 |
Monitoring BCR-ABL in the treatment of chronic myeloid leukemia by polymerase chain reaction.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Bone Marrow Transplantation; Child; Clinical Trials as Topic; Combined Modality Therapy; Disease-Free Survival; Drug Monitoring; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multicenter Studies as Topic; Neoplasm, Residual; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Sensitivity and Specificity | 2006 |
New approaches to the management of Philadelphia-chromosome-positive acute lymphocytic leukemia.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Combined Modality Therapy; Disease-Free Survival; Drug Delivery Systems; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Multicenter Studies as Topic; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Remission Induction; Stem Cell Transplantation; Survival Analysis; Treatment Outcome | 2007 |
Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors.
Topics: Benzamides; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Staging; Piperazines; Practice Guidelines as Topic; Pyrimidines; Recurrence | 2010 |
Role of allogeneic transplantation in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Recurrence; Risk Factors; Transplantation, Homologous | 2008 |
Monitoring after successful therapy for chronic myeloid leukemia.
Topics: Benzamides; Cell Line, Tumor; Cytogenetics; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medical Oncology; Medication Adherence; Neoplasms; Piperazines; Prevalence; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Treatment Outcome | 2012 |
Is going for cure in chronic myeloid leukemia possible and justifiable?
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Theoretical; Multicenter Studies as Topic; Neoplastic Stem Cells; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Recurrence; Treatment Outcome | 2012 |
Imatinib and chronic myeloid leukemia: validating the promise of molecularly targeted therapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Recurrence; Treatment Outcome | 2002 |
Imatinib in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia: current status and evolving concepts.
Topics: Antineoplastic Agents; Antineoplastic Protocols; Benzamides; Clinical Trials as Topic; Drug Interactions; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Imatinib Mesylate; Neoplasm, Residual; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Recurrence; Salvage Therapy | 2002 |
Monitoring bcr-abl by polymerase chain reaction in the treatment of chronic myeloid leukemia.
Topics: Benzamides; Bone Marrow Transplantation; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Monitoring, Physiologic; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Polymerase Chain Reaction; Pyrimidines; Recurrence | 2003 |
Acute lymphoblastic leukemia without the Philadelphia chromosome occurring in chronic myelogenous leukemia with the Philadelphia chromosome.
Topics: Benzamides; Clone Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasms, Second Primary; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Remission Induction | 2003 |
Imatinib mesylate in the treatment of chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Cytarabine; Drug Resistance, Neoplasm; Genes, abl; Humans; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Pyrimidines; Recurrence; Stem Cell Transplantation | 2004 |
Treatment of CML in pediatric patients: should imatinib mesylate (STI-571, Gleevec) or allogeneic hematopoietic cell transplant be front-line therapy?
Topics: Antineoplastic Agents; Benzamides; Child; Clinical Trials as Topic; Decision Making; Dose-Response Relationship, Drug; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Pyrimidines; Recurrence; Survival Analysis; Transplantation, Homologous | 2004 |
AMN107: tightening the grip of imatinib.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Chemical; Mutation; Piperazines; Pyrimidines; Recurrence | 2005 |
Recurrent GI bleeding and surgery following the initial response to imatinib therapy in GIST of the stomach.
Topics: Antineoplastic Agents; Benzamides; Cell Division; Female; Gastrointestinal Hemorrhage; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Recurrence; Stomach Neoplasms; Time Factors; Tomography, X-Ray Computed | 2005 |
[Treatment of hypereosinophilia].
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Benzamides; Chronic Disease; Cyclosporins; Drug Resistance; Eosinophilia; Glucocorticoids; Humans; Hydroxyurea; Imatinib Mesylate; Immunologic Factors; Immunosuppressive Agents; Interferon-alpha; Myeloproliferative Disorders; Parasitic Diseases; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Time Factors | 2006 |
Risk assessment in haemotopoietic stem cell transplantation: disease and disease stage.
Topics: Acute Disease; Adult; Benzamides; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasm Staging; Neoplasms; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Pyrimidines; Recurrence; Risk Assessment; Survival Analysis; Transplantation, Homologous | 2007 |
Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Recurrence; Survival Analysis; Thiazoles; Treatment Outcome | 2007 |
[Imatinib-induced toxic hepatitis: description of two cases and review of the literature].
Topics: Antineoplastic Agents; Benzamides; Chemical and Drug Induced Liver Injury; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prednisone; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Stomach Neoplasms; Time Factors | 2007 |
Imatinib: in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Topics: Antineoplastic Agents; Benzamides; Disease-Free Survival; Dose-Response Relationship, Drug; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Treatment Outcome | 2007 |
Monitoring treatment of chronic myeloid leukemia.
Topics: Adult; Aged; Amino Acid Substitution; Benzamides; Chromatography, High Pressure Liquid; Clinical Trials as Topic; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Monitoring, Physiologic; Piperazines; Point Mutation; Predictive Value of Tests; Protein Kinase Inhibitors; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines; Recurrence; Retrospective Studies | 2008 |
Chronic myeloid leukaemia. STI 571 magnifies the therapeutic dilemma.
Topics: Algorithms; Antineoplastic Agents; Benzamides; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Pyrimidines; Recurrence; Signal Transduction | 2001 |
Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Recurrence | 2001 |
STI-571: current status and future prospects.
Topics: Animals; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Recurrence | 2001 |
59 trial(s) available for imatinib mesylate and Recrudescence
| Article | Year |
|---|---|
Dasatinib-based 2-step induction for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Acute Disease; Adult; Dasatinib; Humans; Imatinib Mesylate; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence | 2022 |
Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: a multicenter phase 2 trial, stop nilotinib (NILSt).
Topics: Adult; Aged; Consolidation Chemotherapy; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pyrimidines; Recurrence; Remission Induction; Substance Withdrawal Syndrome; Withholding Treatment | 2019 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
MR 4log and low levels of NK cells are associated with higher molecular relapse after imatinib discontinuation: Results of a prospective trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Humans; Imatinib Mesylate; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Count; Male; Middle Aged; Pilot Projects; Prospective Studies; Recurrence; Time Factors | 2021 |
Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study.
Topics: Cell Count; Disease-Free Survival; Humans; Imatinib Mesylate; Interferon-gamma; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Receptors, Natural Killer Cell; Recurrence | 2017 |
Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Topics: Adolescent; Adult; Aged; Allografts; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Recurrence; Survival Rate | 2018 |
Allogeneic Hematopoietic Stem Cell Transplantation, Especially Haploidentical, May Improve Long-Term Survival for High-Risk Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Tyrosine Kinase Inhibitor Era.
Topics: Adolescent; Allografts; Child; Child, Preschool; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Induction Chemotherapy; Infant; Male; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Recurrence; Survival Rate | 2019 |
De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial.
Topics: Adult; Aged; Dasatinib; Disease-Free Survival; Drug Administration Schedule; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Recurrence; Treatment Outcome | 2019 |
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.
Topics: Adult; Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Pyrimidines; Recurrence; Treatment Outcome; Withholding Treatment | 2013 |
Imatinib mesylate lacks efficacy in relapsed/refractory peripheral T cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Receptor, Platelet-Derived Growth Factor alpha; Recurrence; Treatment Outcome | 2015 |
Imatinib use immediately before stem cell transplantation in children with Philadelphia chromosome-positive acute lymphoblastic leukemia: Results from Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) Study Ph(+) ALL04.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Japan; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Recurrence; Remission Induction; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2015 |
Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by high non-response and relapse rates.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Fusion Proteins, bcr-abl; Gene Expression; Gene Expression Profiling; Hematopoietic Stem Cell Transplantation; Histone-Lysine N-Methyltransferase; Humans; Ikaros Transcription Factor; Imatinib Mesylate; Middle Aged; Mutation; Myeloid-Lymphoid Leukemia Protein; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Recurrence; Remission Induction; Survival Analysis; Transplantation, Homologous | 2015 |
Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Drug Administration Schedule; Fasciitis; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Joints; Leukemia; Male; Middle Aged; Mycophenolic Acid; Pilot Projects; Prednisone; Range of Motion, Articular; Recurrence; Skin Diseases; Tacrolimus; Transplantation, Homologous | 2015 |
Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study.
Topics: Adult; Age Factors; Aged; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Predictive Value of Tests; Recurrence; Reverse Transcriptase Polymerase Chain Reaction | 2015 |
Long-term follow-up of imatinib plus combination chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Induction Chemotherapy; Male; Methotrexate; Middle Aged; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Recurrence; Remission Induction; Survival Analysis; Transplantation, Homologous; Vincristine | 2015 |
Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome.
Topics: Adolescent; Adult; Aged; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Middle Aged; Neoplasm, Residual; Philadelphia Chromosome; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Predictive Value of Tests; Prognosis; Recurrence; Remission Induction; Secondary Prevention; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Young Adult | 2016 |
Phase II study of imatinib-based chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Consolidation Chemotherapy; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Survival Analysis; Survival Rate; Transplantation, Homologous; Treatment Outcome; Young Adult | 2017 |
Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Bone Marrow; Cladribine; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Piperazines; Pyrimidines; Recurrence; Time Factors | 2008 |
Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis : a Hoosier Oncology Group trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Drug Delivery Systems; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Middle Aged; Oncogene Protein v-akt; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Recurrence; Survival Analysis; Taxoids; Treatment Outcome | 2008 |
Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Prognosis; Prospective Studies; Pyrimidines; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome; Young Adult | 2008 |
The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Benzamides; Disease-Free Survival; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm, Residual; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Pyrimidines; Recurrence; Risk Factors; Stem Cell Transplantation; Time Factors | 2009 |
Impact of age, leukocyte count and day 21-bone marrow response to chemotherapy on the long-term outcome of children with philadelphia chromosome-positive acute lymphoblastic leukemia in the pre-imatinib era: results of the FRALLE 93 study.
Topics: Acute Disease; Adolescent; Age Factors; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Benzamides; Bone Marrow; Bone Marrow Transplantation; Child; Child, Preschool; Cortisone; Female; Humans; Imatinib Mesylate; Infant; Leukocyte Count; Male; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Pyrimidines; Recurrence; Treatment Outcome; Vincristine; Young Adult | 2009 |
Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Female; Glioblastoma; Glioma; Humans; Hydroxyurea; Imatinib Mesylate; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Phthalazines; Piperazines; Pyridines; Pyrimidines; Recurrence; Treatment Outcome | 2009 |
Lack in efficacy for imatinib mesylate as second-line treatment of recurrent or metastatic cervical cancer expressing platelet-derived growth factor receptor alpha.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Female; Humans; Imatinib Mesylate; Middle Aged; Neoplasm Metastasis; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Recurrence; Survival Analysis; Treatment Outcome; Uterine Cervical Neoplasms | 2009 |
Emergence of BCR-ABL-specific cytotoxic T cells in the bone marrow of patients with Ph+ acute lymphoblastic leukemia during long-term imatinib mesylate treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Bone Marrow Cells; CD4-Positive T-Lymphocytes; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunologic Memory; Interferon-gamma; Interleukin-2; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; T-Lymphocytes, Cytotoxic; Time Factors | 2010 |
Targeted agents for chronic myelogenous leukemia: will that be the end of allogeneic bone marrow transplantation for that disease?
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Child; Disease Progression; Disease-Free Survival; Drug Therapy; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Piperazines; Pyrimidines; Recurrence; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Young Adult | 2010 |
A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Daunorubicin; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Recurrence; STAT5 Transcription Factor | 2010 |
Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease Progression; Fibroma; Follow-Up Studies; Humans; Imatinib Mesylate; Middle Aged; Piperazines; Pyrimidines; Recurrence; Survival Analysis | 2011 |
A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor-α or -β: An Italian Sarcoma Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Bone Neoplasms; Chondrosarcoma; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Recurrence; Treatment Outcome | 2011 |
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Drug Administration Schedule; Female; France; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Recurrence; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Survival Rate; Time Factors; Treatment Outcome | 2010 |
Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Benzamides; Child; Disease Progression; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Pyrimidines; Recurrence; Risk Factors; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Young Adult | 2011 |
Adjuvant therapy with imatinib mesylate after resection of primary high-risk gastrointestinal stromal tumors in Japanese patients.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Piperazines; Postoperative Period; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Treatment Outcome | 2013 |
Exploiting antitumor immunity to overcome relapse and improve remission duration.
Topics: Aged; Aged, 80 and over; Benzamides; Disease-Free Survival; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunotherapy; Interferon alpha-2; Interferon-alpha; Interferon-gamma; Lymphocytes; Middle Aged; Piperazines; Polyethylene Glycols; Pyrimidines; Recombinant Proteins; Recurrence; T-Lymphocytes, Cytotoxic | 2012 |
A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Dasatinib; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Thiazoles; Treatment Outcome; Young Adult | 2012 |
Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Recurrence; Survival Analysis; Transplantation, Homologous | 2002 |
Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Bone Marrow; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Sensitivity and Specificity; Survival Rate | 2002 |
Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate.
Topics: Adult; Aged; Benzamides; Blood Cell Count; Dose-Response Relationship, Drug; Female; Humans; Imatinib Mesylate; Immunosuppressive Agents; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Probability; Prognosis; Pyrimidines; Recurrence; Treatment Failure | 2004 |
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Cross-Over Studies; Cytarabine; Cytogenetics; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Prospective Studies; Pyrimidines; Recurrence; Risk Factors; RNA, Messenger; Treatment Outcome | 2003 |
Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Predictive Value of Tests; Pyrimidines; Recurrence; Remission Induction; Survival Analysis | 2004 |
Cytogenetic clonal evolution alone in CML relapse post-transplantation does not adversely affect response to imatinib mesylate treatment.
Topics: Adult; Antineoplastic Agents; Benzamides; Clone Cells; Combined Modality Therapy; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Pyrimidines; Recurrence; Remission Induction | 2004 |
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; beta 2-Microglobulin; Bone Marrow Cells; Follow-Up Studies; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Recurrence; Treatment Outcome | 2004 |
Preemptive treatment of minimal residual disease post transplant in CML using real-time quantitative RT-PCR: a prospective, randomized trial.
Topics: Acute Disease; Adolescent; Adult; Benzamides; Combined Modality Therapy; Disease Progression; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Polymerase Chain Reaction; Prospective Studies; Pyrimidines; Recurrence; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; Transplantation, Homologous | 2004 |
Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571).
Topics: Adult; Benzamides; Blast Crisis; Blood-Brain Barrier; Central Nervous System Neoplasms; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Remission Induction; Tissue Distribution; Treatment Outcome | 2004 |
Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy for posttransplantation chronic myelogenous leukemia relapse.
Topics: Adult; Benzamides; Cytogenetic Analysis; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Predictive Value of Tests; Probability; Prognosis; Pyrimidines; Recurrence; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Salvage Therapy | 2004 |
The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Algorithms; Benzamides; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm, Residual; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Probability; Pyrimidines; Recurrence; Remission Induction; RNA, Messenger; Survival Analysis; Transplantation, Homologous; Treatment Outcome | 2005 |
Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Female; Genes, abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prospective Studies; Pyrimidines; Recurrence; Treatment Outcome | 2005 |
A phase II trial of imatinib in patients with refractory/relapsed myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Proliferation; Disease Progression; Disease-Free Survival; Female; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Male; Middle Aged; Multiple Myeloma; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Recurrence; Retrospective Studies; Survival Rate; Time Factors; Treatment Failure | 2006 |
Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Chronic Disease; Drug Administration Schedule; Europe; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Recurrence; Remission Induction; Stem Cell Transplantation; Survival Rate; Treatment Outcome | 2006 |
Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Disease-Free Survival; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Recurrence; Remission Induction; Withholding Treatment | 2007 |
Reduced-intensity conditioning followed by T-cell depleted allogeneic stem cell transplantation for patients with chronic myeloid leukaemia and minimal residual disease at the time of transplant: high risk of molecular relapse.
Topics: Adult; Benzamides; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Depletion; Male; Middle Aged; Neoplasm, Residual; Pilot Projects; Piperazines; Pyrimidines; Recurrence; Risk; Survival Rate; Transplantation Conditioning; Transplantation, Homologous | 2007 |
Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Brain Stem Neoplasms; Child; Child, Preschool; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Glioma; Humans; Imatinib Mesylate; Male; Piperazines; Pyrimidines; Recurrence; Survival Analysis | 2007 |
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.
Topics: Adolescent; Adult; Aged; Amino Acid Substitution; Antineoplastic Agents; Benzamides; Codon; Dasatinib; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation, Missense; Neoplasm Proteins; Piperazines; Point Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Structure-Activity Relationship; Thiazoles | 2007 |
Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Child; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Haplotypes; Histocompatibility; HLA Antigens; Humans; Imatinib Mesylate; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia; Lymphocyte Transfusion; Male; Methotrexate; Mitoxantrone; Pancytopenia; Peripheral Blood Stem Cell Transplantation; Piperazines; Pyrimidines; Recurrence; Remission Induction; Salvage Therapy; Tissue Donors; Treatment Outcome | 2007 |
Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Ki-67 Antigen; Male; Middle Aged; Pilot Projects; Piperazines; Prognosis; Pyrimidines; Receptor Protein-Tyrosine Kinases; Recurrence; Risk Factors | 2007 |
Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing.
Topics: Adult; Antineoplastic Agents; Benzamides; Biomarkers, Pharmacological; Biopsy; Chronic Disease; Dose-Response Relationship, Drug; Drug Dosage Calculations; Eosinophils; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukocyte Count; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Recurrence; Remission Induction; Withholding Treatment | 2007 |
Marrow fibrosis and its relevance during imatinib treatment of chronic myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Bone Marrow; Disease Progression; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pilot Projects; Piperazines; Primary Myelofibrosis; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Remission Induction; Salvage Therapy | 2007 |
Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Karyotyping; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Predictive Value of Tests; Pyrimidines; Recurrence; Survival Rate; Transplantation, Homologous | 2008 |
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Blood Cell Count; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Phosphorylation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Recurrence; Remission Induction | 2001 |
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Blood Cell Count; Disease-Free Survival; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Pilot Projects; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Recurrence; Remission Induction | 2001 |
195 other study(ies) available for imatinib mesylate and Recrudescence
| Article | Year |
|---|---|
BCR-ABL1 transcript doubling time as a predictor for treatment-free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase.
Topics: Adult; Aged; Biomarkers, Tumor; Child; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Protein Kinase Inhibitors; Real-Time Polymerase Chain Reaction; Recurrence; Remission Induction; Treatment Failure; Young Adult | 2022 |
Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Imatinib Mesylate; Imidazoles; Middle Aged; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyridazines; Recurrence; Young Adult | 2022 |
Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring.
Topics: Adult; Antineoplastic Agents; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Protein Kinase Inhibitors; Recurrence | 2022 |
Patient-specific molecular response dynamics can predict the possibility of relapse during the second treatment-free remission attempt in chronic myelogenous leukemia.
Topics: Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Recurrence; Remission Induction; Treatment Outcome | 2022 |
Chromosomal instability and a deregulated cell cycle are intrinsic features of high-risk gastrointestinal stromal tumours with a metastatic potential.
Topics: Antineoplastic Agents; Cell Cycle; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Recurrence | 2023 |
A Deeply Quiescent Subset of CML LSC depend on FAO yet Avoid Deleterious ROS by Suppressing Mitochondrial Complex I.
Topics: beta Catenin; Chromatin; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Reactive Oxygen Species; Recurrence | 2024 |
Long-term Results of Imatinib Discontinuation in Patients with Chronic-phase Chronic Myeloid Leukemia: A National Multicenter Prospective Study
Topics: Adult; Antineoplastic Agents; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Prospective Studies; Protein Kinase Inhibitors; Quality of Life; Recurrence; Treatment Outcome | 2023 |
Late molecular recurrences in patients with chronic myeloid leukemia experiencing treatment-free remission.
Topics: Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Recurrence; Treatment Outcome | 2020 |
Isolated blast crisis relapse in the central nervous system of a patient treating for a chronic myelogenous leukemia.
Topics: Adolescent; Algeria; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Central Nervous System; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemic Infiltration; Recurrence | 2020 |
A new pre-emptive TKIs strategy for preventing relapse based on BCR/ABL monitoring for Ph+ALL undergoing allo-HCT: a prospective clinical cohort study.
Topics: Adolescent; Adult; Aged; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Protein Kinase Inhibitors; Recurrence; Remission Induction; Transplantation, Homologous; Young Adult | 2021 |
Relevance of treatment-free remission recommendations in chronic phase chronic leukemia patients treated with frontline tyrosine kinase inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Female; France; Fusion Proteins, bcr-abl; Guidelines as Topic; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Patient Selection; Progression-Free Survival; Protein Kinase Inhibitors; Recurrence; Remission Induction; Withholding Treatment; Young Adult | 2021 |
FIP1L1-PDGFRA-Associated Hypereosinophilic Syndrome as a Treatable Cause of Watershed Infarction.
Topics: Adult; Brain; Cerebral Infarction; Coronary Thrombosis; Female; Follow-Up Studies; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Ischemic Stroke; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Receptor, Platelet-Derived Growth Factor alpha; Recurrence; Retrospective Studies; Treatment Outcome | 2021 |
Loss of CD22 expression and expansion of a CD22
Topics: Adult; Aged, 80 and over; Allografts; Antibodies, Bispecific; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Clone Cells; Female; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunophenotyping; Inotuzumab Ozogamicin; Lymphocyte Subsets; Male; Middle Aged; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Salvage Therapy; Sialic Acid Binding Ig-like Lectin 2; Sorafenib; Treatment Failure; Young Adult | 2021 |
Efficacy and prognostic factors of imatinib plus CALLG2008 protocol in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; China; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Multivariate Analysis; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Young Adult | 2017 |
Do polymorphisms in MDR1 and CYP3A5 genes influence the risk of cytogenetic relapse in patients with chronic myeloid leukemia on imatinib therapy?
Topics: Adult; Alleles; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Case-Control Studies; Cytochrome P-450 CYP3A; Cytogenetics; Female; Gene Frequency; Genotype; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Targeted Therapy; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Recurrence; Young Adult | 2017 |
Overexpression of heme oxygenase-1 in bone marrow stromal cells promotes microenvironment-mediated imatinib resistance in chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Apoptosis; Bone Marrow Cells; Cell Line, Tumor; Cellular Microenvironment; Chemokine CXCL12; Chromones; Cytoprotection; Drug Resistance, Neoplasm; Female; Heme Oxygenase-1; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Morpholines; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptors, CXCR4; Recurrence; Signal Transduction; Solubility; Stromal Cells; Survival Analysis; Up-Regulation; Young Adult | 2017 |
Impact of the BCR-ABL1 fusion transcripts on different responses to Imatinib and disease recurrence in Iranian patients with Chronic Myeloid Leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Chromosome Breakpoints; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Polymorphism, Genetic; Recurrence; RNA, Messenger | 2017 |
Haploidentical hematopoietic stem cell transplantation for pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia in the imatinib era.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Haplotypes; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Infant; Male; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; RNA, Messenger; Survival Rate | 2017 |
Philadelphia Chromosome Positive de novo Acute Myeloid Leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Philadelphia Chromosome; Rare Diseases; Recurrence; Remission Induction; Treatment Outcome; Young Adult | 2016 |
CHRONIC MYELOID LEUKEMIA EXPECTED RELAPSE'S CLINICAL-LABORATORY INDEXES.
Topics: Anemia; Antineoplastic Agents; Blood Platelets; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medication Adherence; Prognosis; Recurrence; Retrospective Studies; Risk | 2017 |
Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukem
Topics: Biomarkers, Tumor; Combined Modality Therapy; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunoglobulins; Male; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Receptors, Antigen, T-Cell; Recurrence; Survival Analysis; Treatment Outcome | 2018 |
Recurrent gastrointestinal bleeding in a patient with IgM paraproteinaemia.
Topics: Antineoplastic Agents; Biopsy; Chemotherapy, Adjuvant; Diagnosis, Differential; Gastrointestinal Hemorrhage; Gastrointestinal Stromal Tumors; Humans; Ileal Diseases; Imatinib Mesylate; Immunoglobulin M; Lymph Nodes; Male; Middle Aged; Paraproteinemias; Proto-Oncogene Proteins c-kit; Recurrence; Treatment Outcome; Waldenstrom Macroglobulinemia | 2018 |
Different clonal dynamics of chronic myeloid leukaemia between bone marrow and the central nervous system.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Neoplasms; Central Nervous System Neoplasms; Dasatinib; Drug Administration Schedule; Drug Substitution; Fatal Outcome; Female; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Pyridazines; Pyrimidines; Recurrence | 2018 |
Remission is good - relapse is bad.
Topics: Chromosomes; Humans; Imatinib Mesylate; Immunoglobulins; Neoplasm, Residual; Philadelphia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptors, Antigen, T-Cell; Recurrence | 2018 |
[A Case Survived Long Period after Repeated Operation against the Small Intestinal GIST with Perforation].
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestinal Neoplasms; Intestinal Perforation; Male; Middle Aged; Prognosis; Recurrence; Time Factors | 2018 |
[A Case of Small Intestinal GIST with Long-Term Survival after Tumor Resection for Repeated Peritoneal Recurrence].
Topics: Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestinal Neoplasms; Intestine, Small; Peritoneal Neoplasms; Recurrence; Time Factors | 2017 |
[A Long-Term Survivor Who Are Responding to Sunitinib Treatment for Recurrent Imatinib-Resistant Gastrointestinal Stromal Tumor(GIST)of the Stomach].
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Pyrroles; Recurrence; Stomach Neoplasms; Sunitinib; Time Factors | 2017 |
Ponatinib induces a sustained deep molecular response in a chronic myeloid leukaemia patient with an early relapse with a T315I mutation following allogeneic hematopoietic stem cell transplantation: a case report.
Topics: Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Pyridazines; Recurrence | 2018 |
B-ALL Relapses After Autologous Stem Cell Transplantation Associated With a Shift from e1a2 to e14a2
Topics: DNA Mutational Analysis; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Recurrence; Remission Induction; Transplantation, Autologous | 2019 |
Current treatment of myeloproliferative neoplasias: three scenarios.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloproliferative Disorders; Niacinamide; Nitriles; Polycythemia Vera; Primary Myelofibrosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Recurrence; Remission Induction; Thrombocythemia, Essential; Time Factors; Withholding Treatment | 2020 |
The treatment of children suffering from chronic myelogenous leukemia: a comparison of the result of treatment with imatinib mesylate and allogeneic hematopoietic stem cell transplantation.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Child; Cross-Sectional Studies; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Recurrence; Retrospective Studies; Time Factors; Transplantation, Homologous; Treatment Outcome | 2013 |
[The combination of chronic myeloid leukemia and multiple myeloma in one patient].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Imatinib Mesylate; Induction Chemotherapy; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Piperazines; Polyneuropathies; Pyrazines; Pyrimidines; Recurrence; Watchful Waiting | 2013 |
Is Imatinib Maintenance Required for Patients with Relapse Chronic Myeloid Leukemia Post-Transplantation Obtaining CMR? A Pilot Retrospective Investigation.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pilot Projects; Recurrence; Retrospective Studies; Survival Analysis; Young Adult | 2013 |
[Two cases of recurrent GIST successfully treated with imatinib mesylate at 100mg/day].
Topics: Abdominal Neoplasms; Abdominal Wall; Aged, 80 and over; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Female; Gastrointestinal Stromal Tumors; Humans; Ileal Neoplasms; Imatinib Mesylate; Liver Neoplasms; Middle Aged; Piperazines; Pyrimidines; Recurrence; Stomach Neoplasms; Tomography, X-Ray Computed | 2013 |
Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Drug Administration Schedule; Female; France; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Remission Induction; Risk Factors; Time Factors; Treatment Outcome; Young Adult | 2014 |
[A case of imatinib-resistant gastrointestinal stromal tumor treated with low-dose sunitinib].
Topics: Aged, 80 and over; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Intestinal Neoplasms; Intestine, Small; Male; Peritoneal Neoplasms; Piperazines; Pyrimidines; Pyrroles; Recurrence; Salvage Therapy; Sunitinib | 2013 |
Imatinib and pegylated IFN-α2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Drug Administration Schedule; Drug Monitoring; Female; Fusion Proteins, bcr-abl; Gene Expression; Humans; Imatinib Mesylate; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pilot Projects; Piperazines; Polyethylene Glycols; Prospective Studies; Pyrimidines; Recombinant Proteins; Recurrence; Remission Induction; Time Factors | 2014 |
[Clinical experience of imatinib mesylate for metastatic or recurrent gastrointestinal stromal tumor].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestinal Neoplasms; Male; Middle Aged; Piperazines; Pyrimidines; Recurrence; Stomach Neoplasms; Treatment Outcome | 2014 |
[A case of liver and bone metastasis from gastrointestinal stromal tumor treated using imatinib].
Topics: Aged; Antineoplastic Agents; Benzamides; Bone Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Piperazines; Positron-Emission Tomography; Pyrimidines; Recurrence; Stomach Neoplasms | 2014 |
Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Chromosome Aberrations; Follow-Up Studies; Humans; Imatinib Mesylate; Infant; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Remission Induction; Treatment Outcome; Young Adult | 2014 |
Pneumatosis intestinalis and imatinib mesylate.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Benzamides; Child, Preschool; Dasatinib; Daunorubicin; Dexamethasone; Drug Substitution; Female; Humans; Imatinib Mesylate; Parenteral Nutrition, Total; Piperazines; Pneumatosis Cystoides Intestinalis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Thiazoles; Vincristine | 2014 |
Polymerase I and transcript release factor acts as an essential modulator of glioblastoma chemoresistance.
Topics: Benzamides; Caveolin 1; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glioblastoma; Humans; Imatinib Mesylate; Piperazines; Proteomics; Pyrimidines; Recurrence; RNA-Binding Proteins | 2014 |
[Treatment strategy for recurrent and metastatic gastrointestinal stromal tumors].
Topics: Benzamides; Disease-Free Survival; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Indazoles; Indoles; Liver Neoplasms; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Recurrence; Sulfonamides; Sunitinib | 2014 |
Response to imatinib therapy in adult patients with chronic myeloid leukemia in Saudi population: a single-center study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Disease-Free Survival; Exanthema; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neutropenia; Recurrence; Remission Induction; Retrospective Studies; Saudi Arabia; Thrombocytopenia; Treatment Outcome; Young Adult | 2015 |
Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Acute Disease; Adult; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Expression; Graft vs Host Disease; Haplotypes; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunosuppressive Agents; Male; Middle Aged; Myeloablative Agonists; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Prospective Studies; Recurrence; Siblings; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors | 2015 |
gDNA Q-PCR for clinical monitoring of CML.
Topics: Disease Progression; Genetic Markers; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Polymerase Chain Reaction; Protein Kinase Inhibitors; Recurrence; Remission Induction; RNA, Messenger; Treatment Outcome | 2015 |
[A case of recurrent duodenal gastrointestinal stromal tumor resistant to imatinib and sunitinib, successfully treated with regorafenib].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Resistance, Neoplasm; Duodenal Neoplasms; Fatal Outcome; Female; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Middle Aged; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Recurrence; Sunitinib; Treatment Outcome | 2014 |
[A case of an elderly patient with recurrent GIST, which was effectively treated with low-dose imatinib mesylate].
Topics: Aged, 80 and over; Antineoplastic Agents; Benzamides; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Piperazines; Pyrimidines; Recurrence; Stomach Neoplasms | 2014 |
[A case of recurrent gastrointestinal stromal tumor progressing after interruption of long-term imatinib therapy].
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Piperazines; Pyrimidines; Recurrence; Stomach Neoplasms; Time Factors | 2014 |
[Treatment-free molecular remission achieved by combination therapy with imatinib and IFNα in CML with BIM deletion polymorphism relapsed after stop imatinib].
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Benzamides; Combined Modality Therapy; Gene Deletion; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Membrane Proteins; Middle Aged; Piperazines; Polymorphism, Genetic; Proto-Oncogene Proteins; Pyrimidines; Recurrence; Remission Induction | 2015 |
[A case report of refractory pleural effusion associated with dasatinib in the treatment of chronic myeloied leukemia].
Topics: Dasatinib; Drug Tolerance; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pleural Effusion; Prognosis; Recurrence; Remission Induction | 2015 |
Gender and BCR-ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia.
Topics: Adult; Aged; Alternative Splicing; Antineoplastic Agents; Female; Fusion Proteins, bcr-abl; Gene Expression; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Recurrence; Retrospective Studies; RNA, Messenger; Sex Factors; Treatment Outcome | 2016 |
Imatinib discontinuation for hypereosinophilic syndrome harboring the FIP1L1-PDGFRA transcript.
Topics: Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Receptor, Platelet-Derived Growth Factor alpha; Recurrence; Treatment Outcome | 2016 |
[Outcome of patients with adult acute lymphoblastic leukemia between 2000 and 2013: experience from single center].
Topics: Acute Disease; Adult; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Induction Chemotherapy; Multivariate Analysis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Retrospective Studies; Survival Rate | 2015 |
KIT exon 10 variant (c.1621 A > C) single nucleotide polymorphism as predictor of GIST patient outcome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Line, Tumor; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Multivariate Analysis; Phosphorylation; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Recurrence; Retrospective Studies; Young Adult | 2015 |
Long-Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Incidence; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neoplasm, Residual; Prognosis; Protein Kinase Inhibitors; Recurrence; Retreatment; Retrospective Studies; Treatment Outcome | 2016 |
Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition.
Topics: Clinical Trials as Topic; Erdheim-Chester Disease; Histiocytosis, Langerhans-Cell; Humans; Imatinib Mesylate; Indoles; Inflammation; MAP Kinase Kinase 1; MAP Kinase Signaling System; Mutation; Phosphorylation; Prospective Studies; Proto-Oncogene Mas; Proto-Oncogene Proteins B-raf; Recurrence; Risk; Sulfonamides; Vemurafenib | 2015 |
[Imatinib Combined with VP Low Dose Regiment for Treating Newly Diagnosed Adult Patients with Ph-positive ALL].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cisplatin; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Induction Chemotherapy; Neutropenia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Recurrence; Remission Induction; Transplantation, Homologous; Vindesine | 2015 |
Gastric Antral Vascular Ectasia during the Treatment of Chronic Myelogenous Leukemia with Imatinib Mesylate.
Topics: Aged; Antineoplastic Agents; Female; Gastric Antral Vascular Ectasia; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pyrimidines; Recurrence; Treatment Outcome | 2016 |
Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Recurrence; Retreatment; Time Factors; Treatment Outcome | 2016 |
How many patients can proceed from chronic myeloid leukaemia diagnosis to deep molecular response and long-lasting imatinib discontinuation? A real life experience.
Topics: Antineoplastic Agents; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Prognosis; Protein Kinase Inhibitors; Recurrence; Treatment Outcome | 2017 |
Imatinib-induced long-term remission in a relapsed RCSD1-ABL1-positive acute lymphoblastic leukemia.
Topics: Adolescent; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Male; Oncogene Proteins, Fusion; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins c-abl; Recurrence; Remission Induction; Salvage Therapy | 2016 |
A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Recurrence; Remission Induction; Retreatment; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; France; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Diagnostic Techniques; Neoplasm, Residual; Patient Selection; Predictive Value of Tests; Prospective Studies; Protein Kinase Inhibitors; Recurrence; Risk Factors; Time Factors; Treatment Outcome | 2017 |
[Low-Dose and Interval Administration of Imatinib in a Patient with Liver Metastasis of the Gastrointestinal Stromal Tumor of the Stomach - A Case Report].
Topics: Aged; Antineoplastic Agents; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Recurrence; Stomach Neoplasms; Treatment Outcome | 2017 |
How complete is "complete" molecular response in imatinib-treated chronic myeloid leukemia?
Topics: Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Diagnostic Techniques; Neoplasm, Residual; Piperazines; Pyrimidines; Recurrence; Remission Induction | 2008 |
Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Child; Child, Preschool; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Male; Middle Aged; Models, Molecular; Piperazines; Point Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Recurrence; Salvage Therapy | 2008 |
Molecular responses of late chronic phase chronic myeloid leukemia patients after achieving complete cytogenetic responses with imatinib treatment: a 6-year follow-up.
Topics: Antineoplastic Agents; Benzamides; Disease-Free Survival; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Piperazines; Pyrimidines; Recurrence | 2009 |
Isolated molecular relapse in FIP1L1-PDGFRalpha hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose.
Topics: Adult; Benzamides; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Dosage Calculations; Eosinophils; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukocyte Count; Male; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Patient Compliance; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Recurrence; Remission Induction | 2009 |
[Molecular relapse of chronic myeloid leukemia after discontinuation of imatinib mesylate for maintaining complete molecular response for more than 2 years].
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nucleic Acid Amplification Techniques; Piperazines; Pyrimidines; Recurrence; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors | 2009 |
Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Dasatinib; Dexamethasone; Female; Humans; Imatinib Mesylate; Immunotherapy, Adoptive; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Radiotherapy; Recurrence; Stem Cell Transplantation; Thiazoles; Transplantation, Homologous; Treatment Outcome | 2009 |
[Imaging of gastrointestinal stromal tumors].
Topics: Adult; Aged; Angiography; Antineoplastic Agents; Benzamides; Biopsy; Capsule Endoscopy; Contrast Media; Diagnosis, Differential; Endosonography; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Piperazines; Positron-Emission Tomography; Pyrimidines; Recurrence; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.
Topics: Adolescent; Adult; Aged; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Recurrence; Thiazoles | 2009 |
BCR-ABL-independent and RAS / MAPK pathway-dependent form of imatinib resistance in Ph-positive acute lymphoblastic leukemia cell line with activation of EphB4.
Topics: Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Induction; Ephrin-B2; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; MAP Kinase Signaling System; Middle Aged; Neoplasm Proteins; Phosphorylation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Pyrimidines; ras Proteins; Receptor, EphB4; Recurrence; RNA, Small Interfering | 2010 |
Quantitative detection of BCR-ABL fusion gene and its application in monitoring chronic myeloid leukemia treatment.
Topics: Antineoplastic Agents; Benzamides; Biomarkers; Bone Marrow Transplantation; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Reagent Kits, Diagnostic; Recurrence; Remission Induction | 2011 |
Living donor liver transplantation for acute hepatic failure caused by reactivation of hepatitis B virus infection after chemotherapy for hematologic malignancy: case reports.
Topics: Adult; Antineoplastic Agents; Benzamides; Carrier State; Disease-Free Survival; Hepatitis B; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver Transplantation; Living Donors; Male; Middle Aged; Piperazines; Pyrimidines; Recurrence; Treatment Outcome | 2010 |
Bone marrow or peripheral blood.
Topics: Adult; Benzamides; Bone Marrow Transplantation; Disease-Free Survival; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Peripheral Blood Stem Cell Transplantation; Piperazines; Pyrimidines; Recurrence; Survival Analysis | 2010 |
Improved outcome in patients with chronic myelogenous leukemia after allogeneic hematopoietic stem cell transplantation over the past 25 years: a single-center experience.
Topics: Adult; Benzamides; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Recurrence; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Young Adult | 2011 |
ABVD associated with imatinib for coexisting chronic myeloid leukaemia and relapsed Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bleomycin; Dacarbazine; Doxorubicin; Hodgkin Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Recurrence; Vinblastine | 2010 |
Seven-year response to imatinib as initial treatment versus re-treatment in Chinese patients with chronic myelogenous leukemia in the chronic phase.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Asian People; Benzamides; Chemotherapy, Adjuvant; Child; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neoadjuvant Therapy; Piperazines; Pyrimidines; Recurrence; Time Factors; Treatment Outcome; Young Adult | 2011 |
Clinical characteristics and treatment outcome of pediatric patients with chronic myeloid leukemia.
Topics: Benzamides; Child; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Recurrence; Treatment Outcome | 2010 |
Exploring the curative potential of BCR-ABL1-targeting drugs for chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Benzamides; Drug Administration Schedule; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Remission Induction; Survival Rate; Time Factors; Treatment Outcome | 2010 |
Clinical practice guideline for accurate diagnosis and effective treatment of gastrointestinal stromal tumor in Korea.
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Recurrence; Republic of Korea | 2010 |
Protein expression of cancer testis antigens predicts tumor recurrence and treatment response to imatinib in gastrointestinal stromal tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Piperazines; Pyrimidines; Recurrence; Testis | 2011 |
Isolated central nervous system relapse after nine years of complete molecular remission in a lymphoid blast crisis of chronic myeloid leukemia treated with imatinib.
Topics: Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Central Nervous System; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Recurrence; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction | 2011 |
[Recurrent neutrophilic panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib mesilate and dasatinib].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biopsy; Dasatinib; Drug Eruptions; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neutrophils; Panniculitis; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Skin; Thiazoles | 2011 |
Successful treatment with dasatinib and allogeneic peripheral blood stem cell transplant for imatinib-resistant Philadelphia chromosome-positive acute lymphoblastic leukemia relapsing after bone marrow transplant and donor lymphocyte infusion.
Topics: Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Lymphocyte Transfusion; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Recurrence; Thiazoles; Transplantation, Homologous; Treatment Outcome | 2011 |
Chronic myeloid leukaemia and sickle cell disease: could imatinib prevent vaso-occlusive crisis?
Topics: Adult; Anemia, Sickle Cell; Antineoplastic Agents; Arterial Occlusive Diseases; Benzamides; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Patient Compliance; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Recurrence | 2011 |
[Evidence-based treatment of gastrointestinal stromal tumor (GIST) with tyrosine kinase inhibitors-imatinib and sunitinib].
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Disease Progression; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Recurrence; Sunitinib | 2011 |
[Clonal eosinophilia revealed by recurrent Staphylococcus aureus infection].
Topics: Anti-Bacterial Agents; Benzamides; Biomarkers; Clone Cells; Eosinophilia; Gene Rearrangement; Humans; Imatinib Mesylate; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Recurrence; Risk Factors; Smoking; Staphylococcal Infections; Staphylococcus aureus; Treatment Outcome | 2011 |
α-defensin 1-3 and α-defensin 4 as predictive markers of imatinib resistance and relapse in CML patients.
Topics: alpha-Defensins; Antineoplastic Agents; Benzamides; Biomarkers; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Longitudinal Studies; Peptides, Cyclic; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2011 |
Long-term durability of molecular and chimerism responses in patients treated with imatinib for chronic myeloid leukemia relapse after allogeneic transplantation.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Child; Combined Modality Therapy; Female; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Transfusion; Male; Middle Aged; Piperazines; Pyrimidines; Recurrence; Stem Cell Transplantation; Time Factors; Transplantation Chimera; Transplantation, Homologous; Young Adult | 2011 |
Advances in the surgical management of gastrointestinal stromal tumor.
Topics: Algorithms; Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Nomograms; Piperazines; Prognosis; Pyrimidines; Recurrence; Stem Cell Factor; Tomography, X-Ray Computed | 2011 |
Six-year follow up of imatinib therapy for newly diagnosed chronic myeloid leukemia in Iranian patients.
Topics: Adult; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Iran; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Recurrence; Remission Induction; Retrospective Studies; Treatment Outcome | 2011 |
Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Imatinib Mesylate; Immunity, Innate; Interferon-alpha; Japan; Leukemia, Myeloid, Chronic-Phase; Longitudinal Studies; Male; Middle Aged; Multivariate Analysis; Neoplastic Stem Cells; Piperazines; Pyrimidines; Recurrence; Treatment Outcome | 2012 |
[Twenty-one-year survival case of rectal GIST treated with combined therapies].
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Pyrimidines; Pyrroles; Rectal Neoplasms; Recurrence; Sunitinib; Time Factors | 2011 |
Effectiveness of dasatinib in relapsed CNS, Ph+ ALL that is refractory to radiochemotherapy plus imatinib: a case report.
Topics: Antineoplastic Agents; Benzamides; Central Nervous System Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dasatinib; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Philadelphia Chromosome; Piperazines; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Thiazoles; Transplantation, Homologous; Young Adult | 2011 |
Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph+ ALL: a Children's Oncology Group (COG) study.
Topics: Adolescent; Adult; Antineoplastic Agents; Base Sequence; Benzamides; Child; Child, Preschool; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Infant; Male; Mutation; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Young Adult | 2012 |
Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Theoretical; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Treatment Outcome | 2012 |
BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management.
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Blast Crisis; Disease Management; Disease Progression; Drug Administration Schedule; Drug Monitoring; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Medication Adherence; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Recurrence; Retrospective Studies; RNA, Messenger; RNA, Neoplasm; Time Factors | 2012 |
[Sustained complete molecular remission after cessation of imatinib mesylate treatment in a patient with relapsed chronic myelogenous leukemia after allogeneic stem cell transplantation].
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Recurrence; Remission Induction; Transplantation, Homologous; Withholding Treatment | 2012 |
Chronic therapy in gastrointestinal stromal tumours (GISTs): the big gap between theory and practice.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Gastrointestinal Stromal Tumors; Home Care Services; Humans; Imatinib Mesylate; Medication Adherence; Monitoring, Physiologic; Piperazines; Practice Guidelines as Topic; Precision Medicine; Pyrimidines; Recurrence; Treatment Outcome | 2012 |
Recurrent imatinib-induced hepatotoxicity in a chronic myeloid leukaemia patient successfully managed with prednisone.
Topics: Antineoplastic Agents; Benzamides; Chemical and Drug Induced Liver Injury; Female; Glucocorticoids; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prednisone; Pyrimidines; Recurrence; Remission Induction; Young Adult | 2011 |
Second attempt to discontinue imatinib in CP-CML patients with a second sustained complete molecular response.
Topics: Aged; Aged, 80 and over; Benzamides; Drug Administration Schedule; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Remission Induction; Time Factors; Treatment Outcome | 2012 |
MLPA is a powerful tool for detecting lymphoblastic transformation in chronic myeloid leukemia and revealing the clonal origin of relapse in pediatric acute lymphoblastic leukemia.
Topics: Antineoplastic Agents; Benzamides; Cell Transformation, Neoplastic; Child; Clonal Evolution; Cohort Studies; DNA Copy Number Variations; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Activation; Nucleic Acid Amplification Techniques; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence | 2012 |
Can we safely discontinue imatinib? Searching for new endpoints in CML: a standardized definition of "cure".
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Administration Schedule; Endpoint Determination; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloablative Agonists; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Remission Induction; Risk Factors; Treatment Outcome | 2012 |
The BCL2L11 (BIM) deletion polymorphism is a possible criterion for discontinuation of imatinib in chronic myeloid leukaemia patients.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Benzamides; Chromosome Banding; Drug Administration Schedule; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Introns; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Proteins; Molecular Targeted Therapy; Patient Selection; Piperazines; Polymorphism, Genetic; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrimidines; Recurrence; Remission Induction; Sequence Deletion; Time Factors | 2013 |
[A case of recurrent gastrointestinal stromal tumor with complete response from treatment with reduced dose of imatinib mesylate].
Topics: Aged; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Recurrence; Remission Induction; Stomach Neoplasms; Tomography, X-Ray Computed | 2012 |
Modern treatment of gastric gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Endoscopy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Minimally Invasive Surgical Procedures; Neoadjuvant Therapy; Piperazines; Prognosis; Pyrimidines; Recurrence; Sarcoma; Stomach Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
[A case of recurrent intestinal GIST with long-term survival-beneficial effect of multimodality therapy using high-dose imatinib and surgery].
Topics: Aged; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Jejunal Neoplasms; Piperazines; Pyrimidines; Recurrence; Time Factors | 2012 |
[A case of drug resistant recurrent gastrointestinal stromal tumor treated surgically by resection, partial hepatectomy and diaphragmectomy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Diaphragm; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Indoles; Jejunal Neoplasms; Liver Neoplasms; Male; Peritoneal Neoplasms; Piperazines; Pyrimidines; Pyrroles; Recurrence; Sunitinib | 2012 |
The effect of imatinib therapy on the outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Child; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Retrospective Studies; Survival Analysis; Transplantation, Homologous; Treatment Outcome | 2013 |
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.
Topics: Alleles; Amino Acid Sequence; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Clone Cells; DNA Mutational Analysis; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Mutation; Neoplasm Recurrence, Local; Piperazines; Protein Structure, Tertiary; Pyrimidines; Recurrence; Time Factors | 2002 |
Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans.
Topics: Adult; Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Piperazines; Platelet-Derived Growth Factor; Pyrimidines; Recurrence; Sarcoma; Skin Neoplasms; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2002 |
Efficacy of imatinib mesylate (STI571) in conjunction with alpha-interferon: long-term quantitative molecular remission in relapsed P-190(BCR-ABL)-positive acute lymphoblastic leukemia.
Topics: Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recombinant Proteins; Recurrence; Remission Induction | 2002 |
Tyrosine kinase inhibitor STI571 in the treatment of Philadelphia chromosome-positive leukaemia failing myeloablative stem cell transplantation.
Topics: Adolescent; Adult; Benzamides; Drug Evaluation; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myeloablative Agonists; Piperazines; Pyrimidines; Recurrence; Remission Induction; RNA, Neoplasm; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2002 |
Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML.
Topics: Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow; Cytarabine; Daunorubicin; Disease Progression; Drug Resistance, Neoplasm; Enzyme Inhibitors; Exons; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Neoplastic Stem Cells; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Recurrence; Remission Induction; Salvage Therapy | 2003 |
Molecular response to imatinib mesylate following relapse after allogeneic SCT for CML.
Topics: Benzamides; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Recurrence; Remission Induction; RNA, Messenger; Transplantation, Homologous | 2003 |
Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; DNA, Complementary; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Polymerase Chain Reaction; Pyrimidines; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; RNA; Treatment Outcome | 2003 |
Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib.
Topics: Animals; Benzamides; Blotting, Western; Cell Division; Cell Line; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Mice; Mutagenesis, Site-Directed; Mutation, Missense; Piperazines; Protein Structure, Tertiary; Pyrimidines; Recurrence; Transfection | 2003 |
Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate.
Topics: Benzamides; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neutropenia; Philadelphia Chromosome; Piperazines; Pyrimidines; Recurrence; Thrombocytopenia | 2003 |
Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation.
Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Recurrence; Remission Induction; Transplantation Chimera; Transplantation, Homologous | 2003 |
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Piperazines; Polycythemia Vera; Primary Myelofibrosis; Pyrimidines; Recurrence | 2003 |
PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease.
Topics: Animals; Antineoplastic Agents; Benzamides; Blotting, Western; Bone Marrow; Bone Marrow Transplantation; Cell Line; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance; Fusion Proteins, bcr-abl; Genetic Vectors; Humans; Imatinib Mesylate; Immunophenotyping; Mice; Models, Genetic; mRNA Cleavage and Polyadenylation Factors; Mutation; Myeloproliferative Disorders; Piperazines; Precipitin Tests; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Recurrence; Retroviridae; Spleen; Staurosporine; Time Factors | 2003 |
Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome.
Topics: Adult; Amino Acid Sequence; Animals; Antineoplastic Agents; Base Sequence; Benzamides; Blotting, Western; Cell Division; Cell Line; Cell Survival; Cell Transformation, Neoplastic; Dose-Response Relationship, Drug; Enzyme Inhibitors; Eosinophils; Gene Deletion; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Indoles; Male; Mice; Models, Chemical; Models, Genetic; Molecular Sequence Data; Peptides; Phthalazines; Piperazines; Precipitin Tests; Protein Structure, Tertiary; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Recombinant Fusion Proteins; Recurrence; Tyrosine | 2003 |
Clinical and genetic studies of ETV6/ABL1-positive chronic myeloid leukaemia in blast crisis treated with imatinib mesylate.
Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Enzyme Inhibitors; Fatal Outcome; Follow-Up Studies; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Oncogene Proteins, Fusion; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Recurrence | 2003 |
Imatinib in Philadelphia chromosome-positive chronic phase CML patients: molecular and cytogenetic response rates and prediction of clinical outcome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers; Cytogenetic Analysis; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Diagnostic Techniques; Orosomucoid; Piperazines; Prognosis; Pyrimidines; Recurrence; Remission Induction; RNA, Messenger; Time Factors | 2003 |
Leflunomide analogue FK778 is vasculoprotective independent of its immunosuppressive effect: potential applications for restenosis and chronic rejection.
Topics: Alkynes; Angiogenesis Inhibitors; Animals; Benzamides; Blood Vessels; Constriction, Pathologic; Dihydroorotate Dehydrogenase; Graft Rejection; Imatinib Mesylate; Immunosuppressive Agents; Isoxazoles; Male; Nitriles; Oxidoreductases; Oxidoreductases Acting on CH-CH Group Donors; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Rats; Rats, Wistar; Recurrence; Tunica Intima; Uridine; Vascular Diseases | 2003 |
Current results on the use of imatinib mesylate in patients with relapsed Philadelphia chromosome positive leukemia after allogeneic or syngeneic hematopoietic stem cell transplantation.
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Polymerase Chain Reaction; Pyrimidines; Recurrence; Time Factors; Transplantation, Homologous; Transplantation, Isogeneic; Treatment Outcome | 2003 |
Sustained molecular response with imatinib in a leukemic form of idiopathic hypereosinophilic syndrome in relapse after allograft.
Topics: Adult; Benzamides; Cord Blood Stem Cell Transplantation; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Male; Molecular Diagnostic Techniques; Piperazines; Polymerase Chain Reaction; Pyrimidines; Recurrence; Remission Induction; Transplantation, Homologous | 2004 |
Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a study of the Cancer and Leukaemia Group B.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Chromosomes, Human, Pair 2; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 7; Chromosomes, Human, Pair 9; Female; Humans; Imatinib Mesylate; Karyotyping; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Prospective Studies; Pyrimidines; Recurrence; Remission Induction; Translocation, Genetic | 2004 |
High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib.
Topics: Benzamides; Clone Cells; DNA Mutational Analysis; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Frequency; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Neoplasm Proteins; Oncogene Proteins; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Recurrence | 2004 |
Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission.
Topics: Adult; Benzamides; Cytogenetic Analysis; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Piperazines; Polymerase Chain Reaction; Pyrimidines; Recurrence; Remission Induction; RNA, Messenger; Treatment Outcome | 2004 |
Isolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia and acute lymphoblastic leukemia in patients on imatinib therapy.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow; Central Nervous System Neoplasms; Cytarabine; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methotrexate; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Remission Induction | 2004 |
Early blastic transformation following complete cytogenetic response in a pediatric chronic myeloid leukemia patient treated with imatinib mesylate.
Topics: Adolescent; Benzamides; Blast Crisis; Cytogenetic Analysis; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Lymphocyte Activation; Male; Piperazines; Pyrimidines; Recurrence; Remission Induction; Transplantation, Homologous | 2004 |
Sustained cytogenetic remission induced by imatinib mesylate in a chronic myeloid leukemia patient who had a relapse into lymphoid crisis after allogeneic hematopoietic stem cell transplantation.
Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Female; Genes, abl; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Recurrence; Remission Induction; Transplantation Chimera; Transplantation, Homologous | 2004 |
Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
Topics: Adult; Antineoplastic Agents; Benzamides; Cytogenetics; Female; Fusion Proteins, bcr-abl; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Stem Cell Transplantation; Time Factors; Transplantation Chimera; Transplantation, Homologous; Treatment Outcome | 2004 |
Detection of trisomy 8 in donor-derived Ph- cells in a patient with Ph+ chronic myeloid leukemia successfully treated with Imatinib (STI571) in relapse after allogeneic transplantation.
Topics: Adult; Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplastic Stem Cells; Peripheral Blood Stem Cell Transplantation; Philadelphia Chromosome; Piperazines; Pyrimidines; Recurrence; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Salvage Therapy; Transplantation Chimera; Transplantation, Homologous; Trisomy | 2004 |
Combination treatment of rituximab and imatinib mesylate for simultaneous relapse of MALT lymphoma and a gastrointestinal stromal tumor.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Disease Progression; Doxorubicin; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lymphoma; Lymphoma, B-Cell, Marginal Zone; Middle Aged; Piperazines; Prednisolone; Pyrimidines; Recurrence; Rituximab; Vincristine | 2004 |
Re: Imatinib mesylate administration in the first 100 days after stem cell transplantation.
Topics: Adolescent; Adult; Aged; Benzamides; Graft Rejection; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Stem Cell Transplantation; Time Factors; Treatment Outcome | 2004 |
[Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Recurrence; Remission Induction; Survival Rate | 2004 |
CML cytogenetic relapse after cessation of imatinib therapy.
Topics: Adult; Benzamides; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Recurrence; Reverse Transcriptase Polymerase Chain Reaction | 2005 |
Giant malignant gastrointestinal stromal tumors: recurrence and effects of treatment with STI-571.
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Recurrence; Retrospective Studies; Stromal Cells; Survival Analysis; Time Factors | 2005 |
Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Polymerase Chain Reaction; Prognosis; Pyrimidines; Recurrence; Remission Induction; Risk Factors | 2005 |
Response to imatinib mesylate in a patient with idiopathic hypereosinophilic syndrome associated with cyclic eosinophil oscillations.
Topics: Adult; Antineoplastic Agents; Benzamides; DNA Mutational Analysis; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Piperazines; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Recurrence; Treatment Outcome | 2005 |
Pregnancy under treatment of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML). Outcome of discontinuation of imatinib therapy after achieving a molecular remission.
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Infant, Newborn; Labor, Induced; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Pyrimidines; Recurrence; Remission Induction; Treatment Outcome; Withholding Treatment | 2005 |
Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylate.
Topics: Antigens, CD34; Antineoplastic Agents; Benzamides; Blood Component Removal; Cell Survival; Cells, Cultured; Chromosome Banding; Colony-Forming Units Assay; Cytogenetic Analysis; Feasibility Studies; Filgrastim; Flow Cytometry; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Count; Piperazines; Pyrimidines; Recombinant Proteins; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome | 2005 |
Cancer biology: summing up cancer stem cells.
Topics: Benzamides; Cell Differentiation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Piperazines; Point Mutation; Pyrimidines; Recurrence; Stem Cells; Time Factors; Treatment Outcome | 2005 |
Dynamics of chronic myeloid leukaemia.
Topics: Benzamides; Cell Differentiation; Cell Line, Tumor; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Piperazines; Point Mutation; Pyrimidines; Recurrence; Retrospective Studies; Stem Cells; Time Factors; Treatment Outcome | 2005 |
Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation.
Topics: Antineoplastic Agents; Benzamides; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Recurrence; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Treatment Outcome | 2005 |
Fusion of NUP214 to ABL1 on amplified episomes in T-ALL--implications for treatment.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Artificial Gene Fusion; Benzamides; Gene Amplification; Genes, abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia-Lymphoma, Adult T-Cell; Male; Nuclear Pore Complex Proteins; Piperazines; Plasmids; Pyrimidines; Recurrence | 2005 |
Isolated central nervous system relapse in patients with chronic myeloid leukemia on imatinib mesylate.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Transplantation; Central Nervous System Neoplasms; Chronic Disease; Fatal Outcome; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Pyrimidines; Recurrence; Remission Induction | 2005 |
Imatinib mesylate for refractory acute myeloblastic leukemia harboring inv(16) and a C-KIT exon 8 mutation.
Topics: Benzamides; Chromosome Aberrations; Chromosomes, Human, Pair 16; Exons; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm, Residual; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Recurrence; Remission Induction | 2005 |
Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Benzamides; Drug Synergism; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Transfusion; Male; Middle Aged; Piperazines; Pyrimidines; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; Transplantation, Homologous | 2005 |
Management of chronic myeloid leukaemia in relapse following donor lymphocyte infusion induced remission: a retrospective study of the Clinical Trials Committee of the British Society of Blood & Marrow Transplantation (BSBMT).
Topics: Adult; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Therapy; Enzyme Inhibitors; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytes; Male; Middle Aged; Piperazines; Pyrimidines; Recurrence; Remission Induction; Retrospective Studies; Stem Cell Transplantation; Time Factors; Transplantation, Homologous; Treatment Outcome; United Kingdom | 2005 |
Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Busulfan; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myeloablative Agonists; Piperazines; Pyrimidines; Recurrence; Retrospective Studies; Risk Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2006 |
FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature.
Topics: Adult; Aged; Benzamides; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Eosinophilia; Follow-Up Studies; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Mutation; Oncogene Proteins, Fusion; Piperazines; Prevalence; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Recurrence; Remission Induction; Treatment Outcome | 2006 |
Gene expression changes associated with progression and response in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; DNA-Binding Proteins; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Imatinib Mesylate; Kruppel-Like Transcription Factors; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Peptide Elongation Factor 1; Piperazines; Pyrimidines; Recurrence; Transcription Factors | 2006 |
Intensive chemotherapy and autologous hematopoietic stem cell mobilization, collection and transplantation with simultaneous Imatinib therapy in patients with blast crisis chronic myeloid leukaemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Combined Modality Therapy; Dose-Response Relationship, Drug; Fatal Outcome; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Recurrence; Risk Factors; Transplantation, Autologous; Treatment Outcome | 2006 |
Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.
Topics: Adult; Benzamides; Blast Crisis; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Graft Survival; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Point Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Salvage Therapy; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome | 2006 |
A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation.
Topics: Adult; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Living Donors; Lymphocyte Transfusion; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Remission Induction; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Salvage Therapy; Survival Analysis; Transplantation, Homologous; Treatment Outcome | 2006 |
Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph(+) CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon.
Topics: Adenocarcinoma; Benzamides; Cytogenetic Analysis; Follow-Up Studies; Fusion Proteins, bcr-abl; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasms, Second Primary; Piperazines; Pyrimidines; Rectal Neoplasms; Recurrence; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Transcription, Genetic; Treatment Outcome | 2006 |
[Duodenal gastrointestinal stromal tumors. Report of a case].
Topics: Aged; Antineoplastic Agents; Benzamides; Duodenal Neoplasms; Duodenal Ulcer; Gastrointestinal Hemorrhage; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Pancreaticoduodenectomy; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Radiography; Recurrence | 2006 |
A case of fusariosis in an immunocompromised patient successfully treated with liposomal amphotericin B.
Topics: Abscess; Amphotericin B; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Cytarabine; Foot Dermatoses; Fusarium; Humans; Imatinib Mesylate; Immunocompromised Host; Liposomes; Male; Middle Aged; Muscular Diseases; Onychomycosis; Peripheral Blood Stem Cell Transplantation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Remission Induction; Reoperation; Rituximab; Teniposide; Triazoles; Voriconazole | 2006 |
Hemopoietic stem cell transplantation from a donor with indeterminate HTLV-1 status.
Topics: Adult; Antineoplastic Agents; Benzamides; Blotting, Western; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; HTLV-I Infections; Human T-lymphotropic virus 1; Humans; Imatinib Mesylate; Piperazines; Polymerase Chain Reaction; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Remission Induction; Risk Factors; Tissue Donors; Treatment Outcome | 2007 |
Targeted cancer treatment: resisting arrest.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Differentiation; Humans; Imatinib Mesylate; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Models, Theoretical; Piperazines; Pyrimidines; Recurrence; Stem Cells; Time Factors | 2006 |
Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis.
Topics: Adult; Benzamides; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Recurrence; Transplantation, Homologous | 2007 |
Imatinib-induced Stevens-Johnson syndrome: recurrence after re-challenge with a lower dose.
Topics: Benzamides; Dose-Response Relationship, Drug; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Stevens-Johnson Syndrome | 2007 |
Insufficient outcomes with imatinib mesylate: case report of Ph-positive acute myeloid leukemia evolving from myelodysplastic syndrome.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chromosome Inversion; Chromosomes, Human, Pair 3; Cytogenetic Analysis; Disease Progression; Fatal Outcome; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Recurrence; Treatment Failure | 2007 |
Inv (11)(p15q21) in donor-derived Ph-negative cells in a patient with chronic myeloid leukemia in relapse successfully treated with imatinib mesylate post allogeneic stem cell transplantation.
Topics: Adult; Benzamides; Chromosomes, Human, Pair 11; Female; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Recurrence; Stem Cell Transplantation; Tissue Donors; Transplantation, Homologous | 2007 |
Two successful pregnancies in a chronic myeloid leukemia patient treated with imatinib.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Feeding; Cytarabine; Embryonic Development; Female; Humans; Imatinib Mesylate; Immunologic Factors; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pyrimidines; Recurrence; Remission Induction | 2007 |
Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
Topics: Amino Acid Substitution; Antineoplastic Agents; Benzamides; Bone Marrow Cells; DNA Mutational Analysis; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Mutation; Piperazines; Polymerase Chain Reaction; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Survival Analysis | 2007 |
We should desist using RECIST, at least in GIST.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Metastasis; Piperazines; Pyrimidines; Recurrence; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome | 2007 |
Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia.
Topics: Animals; Benzamides; Cell Proliferation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Mutation; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Recurrence; Risk Factors | 2007 |
Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Binding Sites; Drug Resistance, Neoplasm; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Neoplasm Proteins; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Transduction, Genetic | 2007 |
Platelet-derived growth factor receptor antagonist STI571 (imatinib mesylate) inhibits human vascular smooth muscle proliferation and migration in vitro but not in vivo.
Topics: Animals; Benzamides; Cell Proliferation; Cells, Cultured; Endothelium, Vascular; Humans; Imatinib Mesylate; In Vitro Techniques; Models, Animal; Muscle, Smooth, Vascular; Phosphorylation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Recurrence; Stents; Swine | 2007 |
EBV-positive lymphoproliferative disease with medullary, splenic and hepatic infiltration after imatinib mesylate therapy for chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Cell Proliferation; Female; Herpesvirus 4, Human; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Kidney Medulla; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver; Lymphoproliferative Disorders; Middle Aged; Piperazines; Pyrimidines; Recurrence; Spleen; Translocation, Genetic | 2007 |
Prediction of risk of disease recurrence by genome-wide cDNA microarray analysis in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy.
Topics: Adult; Antineoplastic Agents; Benzamides; Cluster Analysis; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genome, Human; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Pyrimidines; Recurrence; Risk | 2007 |
[Reappearance of t(12;17)-positive primary myelofibrosis following Ph+ CML cell reduction by imatinib].
Topics: Aged; Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 17; Female; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Primary Myelofibrosis; Pyrimidines; Recurrence; Translocation, Genetic | 2007 |
Clonal evolution with +11q 13, t(1;7) and t(1;4) at relapse in a patient with Ph positive acute lymphocytic leukemia (ALL) treated with single agent front line imatinib followed by dasatinib.
Topics: Benzamides; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 4; Clone Cells; Dasatinib; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Thiazoles; Translocation, Genetic | 2007 |
Dasatinib restores full donor chimerism in a patient with imatinib-resistant Ph+ ALL relapsing after unrelated cord blood transplantation.
Topics: Adult; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Chimerism; Cord Blood Stem Cell Transplantation; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Remission Induction; Thiazoles; Time Factors | 2007 |
Complete response after treatment with imatinib in pretreated disseminated testicular seminoma with overexpression of c-KIT.
Topics: Adult; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Lung Neoplasms; Male; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Recurrence; Remission Induction; Salvage Therapy; Seminoma; Testicular Neoplasms; Tomography, Spiral Computed; Treatment Outcome; Up-Regulation | 2007 |
Imatinib in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia: a viewpoint by Barbara Wassmann.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Point Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Salvage Therapy; Survival Rate; Treatment Outcome | 2007 |
Imatinib in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia: a viewpoint by Ronan Swords.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Pyrimidines; Recurrence; Stem Cell Transplantation; Survival Rate; Transplantation, Homologous | 2007 |
Imatinib in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia: a viewpoint by Joseph Brandwein.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Transplantation; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Thiazoles; Transplantation, Homologous | 2007 |
Recurrence of severe pulmonary hypertension following the removal of a lung allograft.
Topics: Adult; Benzamides; Female; Graft Rejection; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Lung Transplantation; Piperazines; Pneumonectomy; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Ventilation-Perfusion Ratio | 2007 |
Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib.
Topics: Adult; Aged; Amino Acid Substitution; Benzamides; Chromatography, High Pressure Liquid; Clinical Trials as Topic; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Point Mutation; Predictive Value of Tests; Protein Kinase Inhibitors; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines; Recurrence; Retrospective Studies | 2008 |
Episodic angioedema with eosinophilia: successful treatment with imatinib.
Topics: Angioedema; Antineoplastic Agents; Benzamides; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Diagnosis, Differential; Eosinophilia; Female; Humans; Imatinib Mesylate; Middle Aged; Piperazines; Pyrimidines; Recurrence | 2008 |
Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Lymphocyte Transfusion; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Stem Cell Transplantation | 2009 |
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.
Topics: Amino Acid Sequence; Amino Acid Substitution; Antineoplastic Agents; Base Sequence; Benzamides; Blast Crisis; Cell Line; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Amplification; Genes, abl; Humans; Hydrogen Bonding; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Sequence Data; Philadelphia Chromosome; Phosphorylation; Piperazines; Point Mutation; Protein Structure, Tertiary; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-crk; Pyrimidines; Recurrence; Signal Transduction | 2001 |
New-age drug meets resistance.
Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Drug Approval; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyrimidines; Recurrence; United States | 2001 |
Treatment of leukemia relapse after allogeneic hematopoietic stem cell transplantation by donor lymphocyte infusion and STI-571.
Topics: Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia; Lymphocyte Transfusion; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Transplantation, Homologous; Treatment Outcome | 2001 |
[STI571: the resistance organizes!].
Topics: Antineoplastic Agents; Benzamides; Drug Design; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gastrointestinal Neoplasms; Gene Amplification; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Pyrimidines; Recurrence | 2001 |
Effects of signal transduction inhibitor 571 in acute myelogenous leukemia cells.
Topics: Benzamides; Cell Division; Cytarabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Imatinib Mesylate; Interleukin-3; Kinetics; Leukemia, Myeloid, Acute; Leukocyte Count; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Recurrence; Signal Transduction; Stem Cell Factor | 2001 |
Transient response to imatinib mesylate (STI571) in a patient with the ETV6-ABL t(9;12) translocation.
Topics: Acute Disease; Adult; Benzamides; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 9; DNA-Binding Proteins; ETS Translocation Variant 6 Protein; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myeloid; Male; Oncogene Proteins, Fusion; Piperazines; Proto-Oncogene Proteins c-ets; Pyrimidines; Recurrence; Repressor Proteins; Translocation, Genetic | 2002 |